fhoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche finance report finance report finance brief key result sale core operate profit margin cer growth sale pharmaceutical diagnostic group change sales mchf mchf chf cer ifrs result sale operating profit net income net income attributable roche shareholder dilute eps chf dividend share chf core result research development core operating profit core eps chf free cash flow operate free cash flow free cash flow change mchf mchf chf cer net debt capitalisation debt equity propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant exchange rate average rate year end december core result core ep earning share exclude noncore item global restructuring plan amortisation impairment goodwill intangible asset allow transparent assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result give therefinance brief roche roche group report solid overall result sale grow constant exchange rate cer core earning share increase exclude impact double charge million swiss franc relate brand prescription drug fee underlie earning grow sale group sale increase cer billion swiss franc growth swiss franc term pharmaceutical sale growth cer continue growth franchise avastin oncology portfolio tamiflu actemraroactemra xolair sale xeloda pegasys decrease diagnostic sale show growth cer professional diagnostic major contributor operating result core operating profit increase cer billion swiss franc decline swiss franc term exclude double charge brand prescription drug fee underlie operating profit grow research development expenditure grow cer billion swiss franc core basis focus oncology neuroscience immunology therapeutic area research development cost group sale ifrs operating result include noncore expense billion swiss franc include billion swiss franc amortisation impairment goodwill intangible asset billion swiss franc global restructuring plan business combination nonoperate result core net financial expense decrease billion swiss franc billion swiss franc drive income divestment equity security low interest expense ifrs net financial expense additionally include loss billion swiss franc noncore major debt restructure net income ifrs net income decrease cer billion swiss franc decline swiss franc term high impairment goodwill intangible asset high global restructuring charge include base effect income billion swiss franc reversal impairment charge result core earning share increase cer swiss franc term exclude impact double charge brand prescription drug fee underlie earning grow cash flow operate free cash flow billion swiss franc decrease cer underlie growth operate business offset high capital expenditure free cash flow increase cer billion swiss franc drive sale equity security low interest payment merger acquisition notably intermune acquisition utilise billion swiss franc cash billion dollar finance new debt issuance repayment debt ahead schedule note bond issue finance genentech transaction repay end financial position net working capital increase cer high level inventory intermune inventory fair value adjustment launch growth key product high safety stock level increase demand key market net debt increase billion swiss franc billion swiss franc mainly intermune acquisition net debt percentage total asset credit rating strong moodys standard poor shareholder return dividend proposal increase dividend swiss franc share represent consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr represent combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statement note roche group consolidate financial statement general accounting principle current liability operating segment information provision contingent liability net financial expense debt income taxis equity attributable roche shareholder business combination chugai global restructuring plan noncontrolle interest property plant equipment employee benefit goodwill pension postemployment benefit intangible asset equity compensation plan inventory earning share nonvoting equity security account receivable statement cash flow marketable security risk management cash cash equivalent relate party noncurrent asset subsidiary associate current asset significant accounting policy account payable subsequent event noncurrent liability report roche management internal control financial reporting report statutory auditor consolidated financial statement report independent auditor internal control financial report multiyear overview supplementary information roche security roche holding ltd basel financial statement note financial statement appropriation available earning report statutory auditor financial statement financial review roche group financial review roche group result sale billion chf core operating profit billion chf cer growth sale net income attributable roche shareholder billions chf core eps chf roche group result show growth core operating activity sale core operating profit constant exchange rate sale increase drive oncology portfolio especially medicine herpositive breast cancer professional diagnostic business core operating profit grow rate sale increase double charge million swiss franc relate brand prescription drug fee solid operating performance combine high income sale equity security low financing cost lead increase core ep constant exchange rate exclude double charge underlie earning grew operate free cash flow billion swiss franc sale sale pharmaceutical division rise billion swiss franc drive oncology portfolio especially franchise grow strong demand actemraroactemra xolair sale increase respectively sale xeloda lower offpatent europe regional growth significant europe latin america diagnostic sale grow consolidate division lead market position major growth area professional diagnostic sale diabetes care increase slightly core operating profit increase pharmaceutical division grow diagnostic division profit pharmaceutical grow good sale growth marketing distribution cost include launch rollout new product notably newly acquire product esbriet investment emerge market increase patient access medicine research development continue investment oncology neuroscience immunology therapeutic area july internal revenue service irs issue final regulation relate brand prescription drug fee fundamentally change key assumption trigger event liability recognition result onetime double charge operating profit impact million swiss franc diagnostic core operating profit grow sale growth offset base effect pension plan change exclude double charge group core operating profit grow operate free cash flow billion swiss franc decrease strong cash generation underlie operation offset high capital investment manufacturing facility site development project free cash flow increase constant exchange rate billion swiss franc drive sale equity security low interest tax payment offset high annual dividend payment roche finance report roche group financial review group continue implementation major global restructuring plan initiate prior year notably programme address longterm profitability diabetes care business diagnostic division total cost group restructure activity billion swiss franc impairment charge billion swiss franc record goodwill intangible asset mainly tissue diagnostic business major debt restructuring refinance group longterm debt result loss billion swiss franc negative factor combine base effect income billion swiss franc reversal impairment charge result total turn increase core net income decrease net income ifrs basis compare average exchange rate average exchange rate swiss franc strong major currency particular japanese yen dollar euro major latin american currency overall impact strongly negative result express swiss franc compare constant exchange rate percentage point impact sale core operating profit core ep january swiss national bank snb announce discontinue minimum exchange rate swiss franc euro consequence stock market switzerland fall significantly value swiss franc increase dramatically roche group fundamental impact foresee example group incur overall cost switzerland token key market europe japan complete value chain mean cost incur local currency swiss franc amount report financial report reflect change exchange rate december group use swiss franc presentation currency consolidated financial statement weaken foreign currency swiss franc negative currency translation impact group consolidated result report swiss franc currency translation sensitivity group result movement foreign currency exchange rate include page roche finance report financial review roche group income statement change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest eps basic chf eps diluted chf core result sale royalty operate income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core ep basic chf core eps diluted chf roche finance report roche group financial review sale sale increase constant exchange rate swiss franc dollar billion swiss franc sale pharmaceutical division rise billion swiss franc drive strong growth franchise avastin tamiflu actemraroactemra xolair mabtherarituxan sale grow region particularly franchise grow xeloda pegasys sale decline xeloda offpatent europe subject generic competition market pegasys subject increase competition new therapy diagnostic division record sale billion swiss franc increase constant exchange rate consolidate lead market position major growth area professional diagnostic represent half division sale grow lead immunodiagnostic business diabete care sale increase despite continue reimbursement cut pricing pressure divisional operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale divisional operating result development result compare pharmaceutical diagnostic corporate group sale increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operate free cash flow increase cer margin percentage point increase core operating result currency translation significant impact operating result negative effect percentage point development group pharmaceutical division core operating margin negative effect percentage point core operate margin diagnostic division pharmaceutical division division increase core operate profit constant exchange rate drive sale growth continue marketing activity new product emerge market include patient access programme research development cost increase focus oncology neuroscience immunology therapeutic area general administration cost increase brand prescription drug fee double charge base effect income change group pension plan result additional oneoff income divestment filgrastim franchise right exclude double charge division core operating profit grow diagnostic division core operating profit drive sale growth operating profit negatively impact base effect pension plan change negative impact cost sale development base effect vat refund million swiss franc exclude factor core operating profit grow ahead sale contain marketing distribution research development cost division continue implementation global restructuring plan diabetes care business continue implementation project roche finance report financial review roche group merger acquisition roche group complete acquisition company total cost acquire asset billion swiss franc cash billion swiss franc fair value contingent consideration arrangement september pharmaceutical division acquire control interest intermune billion swiss franc acquisition add new medicine idiopathic lung fibrosis esbriet roche portfolio esbriet sale million swiss franc record month follow intermune acquisition net negative impact million swiss franc core operating profit postacquisition operating expense intermune notably esbriet launch cost group issue billion dollar debt finance transaction pharmaceutical division complete acquisition seragon pharmaceuticals santaris pharma diagnostic division complete acquisition genia technology bina technology sequence business iquum molecular diagnostic business ariosa diagnostic acquisition close january trophos acquisition expect close quarter transaction foundation medicine expect close second quarter detail give note consolidated financial statement global restructuring plan group continue implementation major global restructuring plan initiate prior year notably programme address longterm profitability diabete care business diagnostic division total cost million swiss franc considerably high cost total million swiss franc result include income million swiss franc reversal previously incur impairment charge bulk drug production unit vacaville site california global restructuring plan cost incur millions chf diagnostic site consolidation plan total global restructuring cost employeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost split plan table reformatte prior year reflect relative development plan include diabete care autonomy speed restructuring plan include closure nutley site associate infrastructure environmental remediation cost include plan pharmaceutical division research development strategic realignment intermune integration specialty care field force europe diagnostic division september roche diabetes care announce autonomy speed initiative enable business focus diabetes care specific requirement speed process decisionmake drive efficiency total cost million swiss franc incur mainly employeerelate cost consultancy cost spend small plan division million swiss franc include cost relate project restructure apply science business site consolidation operational closure site nutley new jersey complete schedule end group currently process divest site work remediate nutley site continue significant additional restructuring expense incur site consolidation cost include relate closure toluca mexico pharmaceutical graz austria diagnostic site roche finance report roche group financial review global restructuring plan total cost million swiss franc major item impairment goodwill arise marcadia acquisition million swiss franc follow exit cardiovascular metabolic disease significant cost include million swiss franc relate field force reduction europe pharmaceutical division specialty care unit intermune integration cost million swiss franc cost million swiss franc arise implementation global outsourcing clinical trial monitoring pharmaceutical division remain minor plan total million swiss franc impairment goodwill intangible asset total impairment charge record goodwill intangible asset million swiss franc compare million swiss franc major tissue diagnostic business impairment charge million swiss franc goodwill million swiss franc product intangible asset impairment product intangible asset represent reassessment latestage product development return predesign phase demonstrate feasibility quality improvement impairment goodwill reflect decrease forecast cash flow follow reassessment combine reduce revenue expectation follow additional reimbursement cut change discount rate impairment testing mention goodwill impairment pharmaceutical division million swiss franc include global restructuring plan addition pharmaceutical division record goodwill impairment charge million swiss franc relate certain previous acquisition impairment charge division total million swiss franc result mainly decision stop development compound detail give note consolidated financial statement pension postemployment benefit disclose financial report base effect operate income million swiss franc past service cost change group pension plan switzerland united kingdom germany million swiss franc record pharmaceutical division million swiss franc diagnostic division remain million swiss franc income allocate corporate mainly attributable previously divest business detail give note consolidated financial statement legal environmental settlement march italian antitrust authority agcm issue verdict allege roche novartis collude artificially differentiate avastin lucentis order foster sale lucentis italy agcm fine roche million euro novartis million euro december administrative tribunal lazio uphold decision agcm roche strongly disagree verdict appeal july roche pay fine protest avoid additional penalty fee prior appeal hear record provision consolidate financial statement correspond expense million swiss franc general administration fine relate interest reimburse roche win case detail give note consolidated financial statement major debt restructuring result low interest rate capital market group decide november restructure debt consist refinance billion dollar note coupon originally issuance billion dollar note coupon major debt restructuring result loss repurchase million swiss franc detail give note consolidated financial statement roche finance report financial review roche group treasury taxation core financing cost billion swiss franc decrease constant exchange rate interest expense amortisation debt discount issue cost low debt repay financial income include million swiss franc income equity security notably gain million swiss franc sale equity security position late core tax expense increase billion swiss franc group effective core tax rate increase compare mainly high percentage core profit contribution come tax jurisdiction relatively high local tax rate average group tax rate notably addition effective tax rate favourably impact retrospective reenactment research development tax credit january mean result include year credit respect net income earning share net income dilute eps decrease respectively constant exchange rate drive cost group restructure activity billion swiss franc impairment charge billion swiss franc combine base effect income billion swiss franc reversal impairment charge result contrast core net income core eps increase respectively core basis exclude noncore item global restructuring cost amortisation impairment goodwill intangible asset loss major debt restructuring exclude impact double charge million swiss franc relate brand prescription drug fee underlie earning grow supplementary net income ep information give page include calculation core eps reconcile core result group publish ifrs result financial position financial position change change mchf mchf chf cer pharmaceuticals net work capital longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operating asset net debt pension income taxis nonoperate asset net total net asset compare start swiss franc strengthen japanese yen russian rouble euro result overall negative translation impact end balance sheet position group level weaken swiss franc dollar year lead positive translation impact net operating asset offset group level natural hedge group dollardenominate debt exchange rate give page impact change exchange rate december reflect number note consolidated financial statement roche finance report roche group financial review pharmaceutical division net work capital increase constant exchange rate trade receivable decrease despite high sale strong collection forfaite activity decrease payment term addition inventory fair value adjustment result intermune acquisition underlie inventory level increase ensure patient supply give increase demand establish product expand market addition new approval recently launch product actemraroactemra subcutaneous formulation kadcyla trade payable increase result improve payment term supplier longterm net operating asset increase significantly goodwill intangible asset billion swiss franc intermune acquisition property plant equipment increase site development project manufacture facility diagnostic decrease net working capital drive increase payable accrue liability high trade payable partially offset high inventory high demand emerge market trade receivables increase driven strong sale partially offset improved collection southern european country longterm net operating asset decrease impairment tissue diagnostic business offset increase goodwill intangible asset genia bina iquum acquisitions increase net debt drive cash outflow acquisition intermune net pension liability increase billion swiss franc low interest rate increase discount define benefit obligation yearend net tax position decrease mainly defer tax effect acquisition accounting increase net pension liability free cash flow free cash flow change change mchf mchf chf cer pharmaceutical diagnostic corporate operating free cash flow treasury activity taxis pay dividend pay free cash flow group operate free cash flow billion swiss franc decrease increase core operating profit offset high capital expenditure increase inventory high restructuring cost free cash flow increase constant exchange rate billion swiss franc drive sale equity security low interest payment low tax payment offset high annual dividend payment roche finance report financial review roche group pharmaceutical division operating result pharmaceutical division operating result change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core ep sale overview pharmaceutical division sale therapeutic area change sale sale therapeutic area mchf mchf cer oncology immunology infectious disease ophthalmology neuroscience therapeutic area total sale pharmaceutical division sale increase constant exchange rate growth drive oncology portfolio especially breast cancer franchise sale growth drive mainly follow key product perjeta herceptin avastin kadcyla actemraroactemra mabtherarituxan product represent portfolio contribute billion swiss franc constant exchange rate sale growth sale xeloda low offpatent key market subject generic competition pegasys sale low increase competition xolair grow tamiflu sale increase mainly severe influenza season sale valcytecymevene continue grow expect entry generic competition delay roche finance report roche group financial review oncology franchise benefit continue strong demand perjeta europe increase use combination herceptin growth driver herceptin uptake kadcyla strong europe avastin show strong growth region strong demand key indication new approval mabtherarituxan grow strongly europe region sale immunology increase strong demand region actemra roactemra monotherapy rheumatoid arthritis growth ophthalmology lucentis sale increase largely high adoption treat diabetic macular edema dme product sale pharmaceutical division sale change sale sale mchf mchf cer oncology avastin herceptin mabtherarituxan tarceva perjeta xeloda kadcyla zelboraf total oncology immunology mabtherarituxan actemraroactemra xolair cellcept pulmozyme total immunology infectious disease pegasys tamiflu valcytecymevene rocephin total infectious disease ophthalmology lucentis total ophthalmology neuroscience madopar total neuroscience therapeutic area activasetnkase neorecormonepogin mircera nutropin total therapeutic area total sale total mabtherarituxan sale million swiss franc million swiss franc split oncology immunology franchise roche finance report financial review roche group mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukemia cll follicular lymphoma rheumatoid arthritis granulomatosis polyangiitis gpa microscopic polyangiitis mpa sale growth result increase use oncology rheumatoid arthritis indication sale oncology franchise stable competitor product franchise sale grow increase share shorter dosing interval subcutaneous formulation mabtherarituxan nhl approve europe australia russia chile mabtherarituxan regional sale change sale sale mchf mchf cer united states europe japan international total sale sale stable result benefit release sale reserve program exclude base impact million swiss franc sale rise sale show strong growth europe sale drive increase market share firstline treatment cll sale benefit decrease mandatory rebate germany international market sale decline economic condition fourth quarter russia franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer overall growth franchise herceptin sale strong perjeta kadcyla grow strongly global rollout continue herceptin regional sale change sale sale mchf mchf cer united states europe japan international total sale perjeta regional sale change sale sale mchf mchf cer united states europe japan international total sale kadcyla regional sale change sale sale mchf mchf cer united states europe japan international total sale roche finance report roche group financial review herceptin sale grow base result benefit release sale reserve program exclude impact million swiss franc sale rise growth result increase usage treatment breast cancer combination perjeta europe sale increase good uptake herceptin subcutaneous formulation available market sale japan grow increase usage combination perjeta international region grow subregion growth latin america result high demand public sector sale asiapacific grow result improve patient access perjeta sale grow region treat metastatic breast cancer significantly europe uptake strong germany france growth benefit use presurgical set kadcyla sale grow region strong uptake europe addition good initial uptake japan avastin advanced colorectal breast lung kidney cervical ovarian cancer relapse glioblastoma type brain tumour demand strong sale grow region avastin regional sale change sale sale mchf mchf cer united states europe japan international total sale sale increase driven grow demand colorectal cervical ovarian cancer treatment base result benefit release sale reserve program exclude impact million swiss franc sale rise europe sale grow result increase demand ovarian cancer indication japan sale increase strong demand treatment breast cancer ovarian cancer malignant glioma international region growth drive launch ovarian cancer uptake colorectal cancer lucentis wet agerelate macular degeneration amd macular edema follow retinal vein occlusion rvo diabetic macular edema dme lucentis regional sale change sale sale mchf mchf cer united states total sale sale grew drive largely increase adoption lucentis treating dme actemraroactemra rheumatoid arthritis systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis growth region drive strong demand monotherapy early use rheumatoid arthritis actemraroactemra regional sale change sale sale mchf mchf cer united states europe japan international total sale demand particularly strong europe sale grow strongly japan significant uptake new subcutaneous formulation roche finance report financial review roche group tarceva advanced nonsmall cell lung nsclc pancreatic cancer tarceva regional sale change sale sale mchf mchf cer united states europe japan international total sale sale low globally growth japan offset decline sale europe international region increase impact competitor product pegasys hepatitis pegasys regional sale change sale sale mchf mchf cer united states europe japan international total sale sale decrease mainly europe increase competition new generation hepatitis therapie international region growth latin america public sector sale offset low sale eastern europe middle east africa region sale japan increase increase usage triple combination therapy xeloda colorectal stomach breast cancer xeloda regional sale change sale sale mchf mchf cer united states europe japan international total sale sale decline region follow entry generic competitor key market anemia franchise neorecormonepogin mircera anemiarenal anemia decline highly competitive market combine sale roche neorecormon chugais epogin epoetin beta decline follow previous period sustain decline increase sale mircera partly compensate neorecormonepogin regional sale change sale sale mchf mchf cer united states europe japan international total sale roche finance report roche group financial review mircera regional sale change sale sale mchf mchf cer united states europe japan international total sale mircera sale growth result new outlicensing partnership underlie growth international region cellcept prevention solid organ transplant rejection cellcept regional sale change sale sale mchf mchf cer united states europe japan international total sale sale decline globally continue generic competition tamiflu influenza tamiflu regional sale change sale sale mchf mchf cer united states europe japan international total sale sale grow mainly epidemic influenza season increase sale europe pandemic use addition sale increase japan early onset flu season result high demand fourth quarter zelboraf braf mutationpositive metastatic melanoma zelboraf regional sale change sale sale mchf mchf cer united states europe japan international total sale sale decline significant competition increase international region result good uptake market brazil argentina roche finance report financial review roche group pharmaceutical division sale region change sale sale region mchf mchf cer united states europe japan international eemea latin america asiapacific region total sale eastern europe middle east africa united states sale grew lead franchise tamiflu xolair avastin actemraroactemra base result benefit release sale reserve program exclude impact million swiss franc sale rise lead product oncology medicine mabtherarituxan avastin herceptin sale billion swiss franc billion swiss franc billion swiss franc respectively addition xolair actemra roactemra significant growth driver tamiflu sale increase xolair sale benefit approval treat form chronic hive growth negatively impact decline xeloda offpatent europe sale increase led breast cancer franchise high demand mabtherarituxan avastin mabtherarituxan sale grow increase market share follicular lymphoma chronic lymphocytic leukemia lower mandatory rebate avastin grow demand ovarian breast cancer addition continue sale growth actemraroactemra high tamiflu sale pandemic stocking growth partially offset low sale xeloda loss exclusivity pegasys japan sale grow major growth driver franchise increase demand avastin breast cancer ovarian cancer malignant glioma actemraroactemra significant uptake new subcutaneous form strong growth edirol bonviva sale international sale increase drive volume growth latin america subregion particular brazil argentina growth latin america mainly franchise oncology product especially avastin mabtherarituxan asiapacific main driver growth franchise mabthera rituxan actemraroactemra sale china grow high franchise mabtherarituxan offset decline sale tarceva base effect strong tamiflu sale eastern europe middle east africa subregion low sale russia result economic condition fourth quarter middle east follow distribution change pharmaceutical division sale lead emerge market change sale sale country mchf mchf cer brazil china india mexico russia south korea turkey total sale total sale key emerge market stable growth china brazil offsetting impact economic condition fourth quarter russia public sector inventory management mexico roche finance report roche group financial review operating result pharmaceutical division royalty operating income change mchf mchf cer royalty income income outlicense agreement income disposal product total ifrs core basis increase royalty operating income constant exchange rate high income product disposal majority income arise divestment gain million swiss franc sale filgrastim franchise right amgen royalty income increase high sale eylea lucentis humira pharmaceutical division cost sale change mchf mchf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis business combination inventory fair value adjustment global restructuring plan amortisation intangible asset total ifrs basis core cost sale increase constant exchange rate line growth sale manufacturing cost good sell period cost increase sale royalty expense slightly high impact high tamiflu sale offset base impact additional royalty expense sanofi arbitration expense collaboration profitshare agreement increase mainly grow sale xolair noncore cost include writeoff inventory fair value adjustment intermune acquisition accounting far relate sale remain million swiss franc adjustment expense acquire inventory sell comparative global restructuring cost site consolidation activity include income million swiss franc reversal previously incur impairment charge vacaville site california amortisation intangible asset increase esbriet intangible asset acquire intermune acquisition pharmaceutical division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis marketing distribution core cost increase constant exchange rate percentage sale increase marketing effort support newly launch product perjeta kadcyla establish oncology product key market intermune acquisition lead increase cost launch esbriet investment enable continue growth emerge market increase patient access medicine bad debt expense million swiss franc record income million swiss franc result increase credit risk certain customer international sale region release income allowance southern europe comparative period roche finance report financial review roche group pharmaceutical division research development change mchf mchf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core research development cost increase constant exchange rate percentage sale rise continued investment oncology franchise notably pdltargete therapy alectinib recently approve japan neuroscience therapeutic area remain key area programme multiple sclerosis alzheimer disease immunology therapeutic area low spend cardiovascular metabolism follow previously announce reorganisation pharmaceutical division research development activity termination aleglitazar addition pharmaceutical division invest million swiss franc inlicense pipeline compound technology capitalise intangible asset global restructuring cost million swiss franc record consist mainly employeerelate cost result implementation outsource model clinical trial monitoring activity impairment charge million swiss franc result mainly decision stop development compound pharmaceutical division general administration change mchf mchf cer administration pension past service cost gain loss disposal property plant equipment gain loss divestment subsidiary business taxis capital taxis general item general administration core basis global restructuring plan impairment goodwill alliance business combination legal environmental settlement pension settlement gain loss total ifrs basis general administration core cost increase constant exchange rate percentage sale increase reflect base effect income record past service cost change group pension plan switzerland million swiss franc increase administration cost mainly result cost implement global efficiency initiative enhance procurement process relate system significant increase business taxis include cost brand prescription drug fee million swiss franc million swiss franc july internal revenue service irs issue final regulation relate fee fundamentally change key assumption trigger event liability recognition result onetime double charge operating profit impact million swiss franc noncore cost include impairment goodwill marcadia acquisition follow exit cardiovascular metabolic disease impairment dedicated goodwill relate certain previous acquisition alliance business combination cost include mainly transaction fee relate cost intermune acquisition legal environmental settlement cost million swiss franc record respect fine pay italian antitrust authority allegation avastin lucentis italy roche strongly disagree allegation appeal note consolidated financial statement detail matter roche finance report roche group financial review roche pharmaceutical chugai subdivisional operating result pharmaceutical subdivisional operating result million chf roche pharmaceutical pharmaceutical chugai division sale external customer division core operate profit margin sale external customer operate profit margin sale external customer operate free cash flow margin sale pharmaceutical division total core operating profit operating profit include elimination million swiss franc million swiss franc unrealise inter company profit roche pharmaceutical chugai fall exchange rate japanese yen negative impact approximately chugai result express swiss franc sale external customer chugai increase japanese yen main driver franchise avastin sale actemraroactemra roche pharmaceutical significantly high chugais core operating profit increase impact product mix japanese yen depreciation cost sale operate free cash flow chugai decrease mainly result increase account receivable high investment property plant equipment manufacturing research facility financial position pharmaceutical division net operating asset movement movement change change transactions cta mchf mchf chf cer mchf mchf trade receivables inventory trade payable net trade work capital receivablespayable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give consolidated financial statement reconciliation balance sheet information give roche finance report financial review roche group currency translation effect balance sheet amount compare start swiss franc weaken dollar lead positive translation impact net operating asset december minor negative translation effect swiss franc strengthen japanese yen euro exchange rate give page impact change exchange rate december reflect number note consolidated financial statement net work capital increase constant exchange rate increase inventory offset increase payable reduction trade receivable trade receivables decrease despite high sale strong collection forfaite receivables italy short payment term february payment receive spain montoro plan addition inventory fair value adjustment intermune acquisition underlie inventory level increase ensure continuity supply patient increase demand establish product especially emerge market inventory increase recently launch product actemraroactemra subcutaneous formulation kadcyla trade payable increase result improve payment term supplier longterm net operating asset grow significantly increase goodwill intangible asset billion swiss franc mainly relate intermune seragon acquisition increase provision contingent consideration legal restructuring provision property plant equipment significant investment continue site development project manufacture facility particular switzerland china free cash flow pharmaceutical division operate free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale detail breakdown provide pharmaceutical division operate free cash flow stable billion swiss franc increase cash generation underlie business compensate increase investment property plant equipment increase net working capital note comment financial position operating profit net operating cash adjustment increase core operating profit increase difference mainly significant noncash item include income change group pension plan increase capital expenditure property plant equipment reflect significant investment site development manufacturing expansion project particularly switzerland china roche finance report roche group financial review diagnostic division operating result diagnostic division operating result change change mchf mchf chf cer ifrs result sale royalty operate income cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operate income cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow margin sale page definition core result core ep sale diagnostic division continue increase sale growth constant exchange rate billion swiss franc professional diagnostic sale growth main growth contributor lead immunodiagnostic business molecular diagnostic sale increase growth underlie molecular business partly offset decline genome sequence business diabetes care sale despite continue challenge market environment notably growth tissue diagnostic drive advanced staining franchise diagnostic division sale business area change sale sale business area mchf mchf cer professional diagnostic diabetes care molecular diagnostic tissue diagnostic total sale roche finance report financial review roche group professional diagnostic increase sale business area major contributor divisional performance region growth primarily drive immunodiagnostic business represent divisional sale growth support clinical chemistry business coagulation monitor elecsys syphilis immunoassay antimllerian hormone test launch new instrument cobas launch fully automate urinalysis combine urine strip testing digital microscopy professional diagnostic regional sale change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale professional diagnostic business grow region especially asiapacific emea strong sale china germany north america region strong growth report clinical chemistry immunodiagnostic business diabetes care sale despite continue challenge market condition blood glucose monitor portfolio major market like sale premium product accuchek mobile grow accuchek avivaperforma sales accuchek insight system insulin delivery system combine insulin pump blood glucose meter accuchek connect webbase blood glucose meter support diabete care selfmanagement launch europe diabetes care regional sale change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale sale north america medicare reimbursement cut strip lower pump sale change number reimburse strip canada offset increase sale emea region asiapacific latin america region mainly drive china argentina progress implementation specific initiative roche diabete care initiate goal streamline process decisionmake drive efficiency continue develop innovative solution molecular diagnostic sale grow underlie molecular business major contribution come virology portfolio hpv assay partly offset sale decline genome sequence business molecular diagnostic regional sale change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale regionally growth drive north america cobas systems integrate fully automate molecular testing system launch blood screen virology assay authoritie australia canada approve cobas hpv test firstline primary screening cervical cancer diagnostic test mrsasa cdifficile hsv launch cemarke country expand menu cobas roche molecular diagnostic acquire genia technology develop singlemolecule semiconductorbase dnasequencing platform nanopore technology bina technology develop commercialise binagms support multiple sequence technology iquum focus develop pointofcare product molecular diagnostic market roche finance report roche group financial review follow reorganisation apply science business area realtime pcr technology nap nucleic acid purification portfolio biochemical reagent molecular diagnostic business sale sequence business report result molecular diagnostic tissue diagnostic sale rise drive growth advance staining portfolio cintec franchise cervical cancer diagnosis grow show continue good uptake tissue diagnostic regional sale change sale sale mchf mchf cer europe middle east africa emea north america rest world total sale regionally growth drive emea north america despite reimbursement change region growth drive advanced staining portfolio sale asiapacific grow china main market revenue exist external partnership show continued growth impairment million swiss franc goodwill million swiss franc product intangible asset record tissue diagnostic factor lead impairment return latestage product development project predesign phase lead decrease forecast cash flow combine reduce revenue expectation follow additional reimbursement cut change discount rate result impairment diagnostic division sale region change sale sale region mchf mchf cer europe middle east africa emea north america asiapacific latin america japan total sale sale growth diagnostic division drive asiapacific emea north america region mainly professional diagnostic sale increase asiapacific drive strong performance china governmental healthcare investment public demand division expand presence wide portfolio emea region division large market sale increase lead growth professional diagnostic latin america region sale increase drive mainly growth professional diagnostic diabetes care sale japan remain stable roche finance report financial review roche group diagnostic division sale lead emerge market change sale sale country mchf mchf cer brazil china india mexico russia south korea turkey total sale market contribute sale growth mainly professional diagnostic business area growth china explain operating result diagnostic division royalty operating income change mchf mchf cer royalty income income outlicense agreement income disposal product total ifrs core basis increase constant exchange rate drive high outlicensing income mainly molecular diagnostic diagnostic division cost sale change mchf mchf cer manufacturing cost good sell period cost royalty expense impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost sale increase constant exchange rate primarily increase manufacturing cost good sell period cost result volume growth additionally period cost include onetime vat refund million swiss franc relate meter placement cost sale ratio compare global restructuring cost incur mainly reorganisation diabetes care business course autonomy speed project reorganisation apply science business closure site graz austria amortisation product intangible decrease intangible asset fully amortise addition product intangible asset impairment charge million swiss franc incur tissue diagnostic diabetes care roche finance report roche group financial review diagnostic division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis marketing distribution core cost constant exchange rate reflect high spending professional diagnostic drive marketing support sale force expense partially offset low bad debt expense north america marketing distribution cost decrease significantly low field force expense decrease offset high expense asiapacific latin america region penetrate emerge market core basis marketing distribution cost percentage sale compare global restructuring cost mainly initiative improve efficiency marketing distribution activity reorganisation diabetes care applied science business diagnostic division research development change mchf mchf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core research development cost increase constant exchange rate drive increase spending generation sequence follow acquisition genia professional diagnostic core platform investment immunodiagnostic workflow automation coagulation hematology pointofcare percentage sale research development core cost decrease global restructuring cost mainly closure site graz austria reorganisation apply science business impairment charge million swiss franc tissue diagnostic business follow return latestage product development project predesign phase diagnostic division general administration change mchf mchf cer administration pension past service cost gain loss disposal property plant equipment business taxis capital taxis general item general administration core basis global restructuring plan impairment goodwill intangible asset alliance business combination legal environmental settlement pension settlement gain loss total ifrs basis general administration core cost increase constant exchange rate base effect onetime income million swiss franc record past service cost change group pension plan switzerland exclude base effect core cost increase business taxis include cost million swiss franc medical device excise tax percentage sale core cost increase global restructuring cost mainly project reorganisation diabetes care addition goodwill impairment charge million swiss franc incur tissue diagnostic business area roche finance report financial review roche group financial position diagnostic division net operating asset movement movement change change transactions cta mchf mchf chf cer mchf mchf trade receivables inventory trade payable net trade work capital receivablespayable net work capital property plant equipment goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give consolidated financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start swiss franc weaken dollar lead positive translation impact net operating asset december partly offset negative translation effect swiss franc strengthen euro diagnostic division significant net asset position japanese yen appreciation swiss franc japanese yen minor impact exchange rate give page impact change exchange rate december reflect number note consolidated financial statement net work capital net trade working capital increase drive increase inventory account receivables partially offset increase trade payable inventory increase high demand emerge market notably china turkey brazil trade payable increase result improve payment term supplier trade receivable increase strong sale partially offset improved collection factor initiative southern europe february payment receive spain montoro plan net liability receivablespayable increase increase payable offset vat receivables longterm net operating asset decrease constant exchange rate increase goodwill intangible asset genia iquum bina acquisition offset impairment tissue diagnostic business property plant equipment increase slightly site expansion project germany provision increase creation provision million swiss franc contingent consideration arrangement genia iquum bina acquisition roche finance report roche group financial review free cash flow diagnostic division operate free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow sale detail breakdown provide operate free cash flow diagnostic division billion swiss franc cash generation business offset increase net working capital note comment financial position high investment property plant equipment operating profit net cash adjustment increase core operating profit increase capital expenditure property plant equipment come mainly site expansion germany roche finance report financial review roche group corporate operating result corporate operating result summary change mchf mchf cer administration pension past service cost business taxis capital taxis general item general administration cost core basis global restructuring plan alliance business combination legal environmental settlement pension settlement gain loss total cost ifrs basis financial position net work capital longterm net operating asset net operating asset free cash flow operate free cash flow page definition core result core eps general administration core cost increase constant exchange rate base effect income million swiss franc record past service cost change group pension plan switzerland exclude cost decrease reduce project expense administration expense increase high spending legal corporate activity total cost ifrs basis decrease legal environmental settlement expense corporate operating free cash flow show low outflow compare drive low spend foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report cer swiss francs change cer change chf pharmaceutical division sale core operate profit diagnostic division sale core operating profit group sale core operating profit roche finance report roche group financial review exchange rate swiss franc december average december average usd eur jpy compare average exchange rate average exchange rate swiss franc strong currency particular dollar number latin american currency japanese yen impact strongly negative income statement free cash flow result express swiss franc compare constant exchange rate sale development result negative impact percentage point equivalent billion swiss franc translate swiss franc currency translation exposure operating profit mitigate group majority cost base locate outside switzerland sensitivity group sale core operating profit absolute term movement average foreign currency exchange rate swiss franc show table january swiss national bank snb announce discontinue minimum exchange rate swiss franc euro consequence stock market switzerland fall significantly value swiss franc increase dramatically roche group fundamental impact foresee example group incur overall cost switzerland token key market europe japan complete value chain mean cost incur local currency swiss franc impact change exchange rate december reflect number note consolidated financial statement group use swiss franc presentation currency consolidated financial statement weaken foreign currency swiss franc negative currency translation impact group consolidated result report swiss franc currency translation sensitivity group result movement foreign currency exchange rate show currency sensitivity impact change average exchange rate sale core operating profit versus swiss franc mchf mchf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost mainly concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany obviously large majority chugais cost denominate japanese yen roche finance report financial review roche group treasury taxation result treasury taxation result change change mchf mchf chf cer ifrs result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest financial position treasury taxation net debt pension income taxis financial noncurrent asset derivative net collateral net interest payable nonoperate asset net total net asset liability free cash flow treasury taxation treasury activity taxis pay dividend pay total page definition core result core ep financing cost finance cost ifrs basis high constant exchange rate mainly loss major debt restructure million swiss franc core financing cost low drive decrease interest expense reflect continue repayment debt incur finance genentech transaction new debt issue late finance intermune acquisition major impact financing cost net interest cost define benefit pension plan decrease million swiss franc improved funding status end analysis financing cost give note consolidated financial statement roche finance report roche group financial review financial income expense financial income expense net income million swiss franc compare expense million swiss franc reason income equity security million swiss franc million swiss franc major factor sale equity security position late result income million swiss franc interest income income debt security million swiss franc environment continue low interest rate net foreign exchange result reflect hedging cost loss million swiss franc compare loss million swiss franc analysis financial income expense give note consolidated financial statement detail group hedge arrangement give note income taxis group effective core tax rate increase percentage point mainly high percentage core profit contribution come tax jurisdiction relatively high local tax rate average group tax rate notably addition effective tax rate include retrospective reenactment research development tax credit mean result include year tax credit respect ifrs result include noncore expense come tax jurisdiction relatively high tax rate group effective tax rate decrease effective tax rate ifrs result compare core result impact partially offset fact ifrs result include goodwill impairment tax deductible detail group income tax position give note consolidated financial statement analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate mchf mchf mchf mchf group effective tax rate core basis global restructuring plan goodwill intangible asset alliance business combination legal environmental major debt restructuring equity compensation plan group effective tax rate ifrs basis financial position increase net debt mainly outflow business combination billion swiss franc partially offset free cash flow billion swiss franc increase net pension liability reflect low interest rate lead discount define benefit obligation high net tax position decrease mainly defer tax effect acquisition accounting increase net pension liability december group hold financial longterm asset market value billion swiss franc consist holding biotechnology company acquire context licensing transaction scientific collaboration weaken swiss franc dollar year lead translation impact group dollardenominate debt increase net debt swiss franc term impact change exchange rate december reflect number note consolidated financial statement free cash flow sale equity security low interest payment lead decrease cash outflow treasury activity billion swiss franc taxis pay billion swiss franc decrease constant exchange rate mainly prepayment tax dividend payment billion swiss franc increase billion swiss franc compare reflect increase roche group dividend roche finance report financial review roche group cash flow net debt operate free cash flow billion chf free cash flow billion chf free cash flow millions chf pharmaceutical diagnostic corporate group operate profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operating profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment investment intangible asset operate free cash flow treasury activity taxis pay dividend pay free cash flow operate free cash flow billion swiss franc strong underlie cash generation business capital expenditure project restructure initiative result decrease constant exchange rate net work capital increase notably inventory cash outflow treasury activity lower billion swiss franc sale equity security reduce interest payment total taxis pay billion swiss franc decrease prepayment tax total dividend pay high increase annual roche group dividend free cash flow billion swiss franc high constant exchange rate sale equity security low interest tax payment offset increase dividend roche finance report roche group financial review net debt millions chf december cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow transaction equity instrument business combination net divestment subsidiary hedge collateral arrangement currency translation fair value movement change net debt period december cash cash equivalent marketable security longterm debt shortterm debt net debt end period net debt currency profile millions chf cash marketable security debt dollar euro swiss franc japanese yen pound sterling total dollardenominate debt include bond note denominate euros swiss franc pound sterling swap dollar financial statement economic characteristic equivalent dollardenominate bond note net debt position group december billion swiss franc increase billion swiss franc december increase net debt mainly billion swiss franc outflow business combination partially offset free cash flow billion swiss franc include annual dividend payment billion swiss franc transaction equity hedge group employee stock option programme total billion swiss franc group enter derivative contract party hedge foreign exchange risk arise bond note issue currency dollar time collateral agreement enter derivative counterpartie mitigate counterparty risk cash collateral balance decrease billion swiss franc collateral balance relation hedge nonus dollardenominate bond note mainly sensitive foreign exchange rate dollar euro pound sterling currently collateral balance move approximately million dollar foreign exchange rate simultaneously redemption repurchase bond note note consolidated financial statement impact liquid fund impact net debt position roche finance report financial review roche group pension postemployment benefit postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan million swiss franc million swiss franc plan classify define benefit plan group potential obligation minor relatively remote possibility arise plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource define benefit plan expense group define benefit plan million swiss franc million swiss franc increase mainly base effect past service income million swiss franc partly offset decrease current service cost million swiss franc drive high discount rate begin compare begin base revise actuarial assumption end expense group define benefit plan expect approximately million swiss franc drive low discount rate begin estimate pension expense include settlement past servicecurtailment effect arise year operate income million swiss franc record past service cost change group pension plan switzerland germany represent onetime impact adjustment pension liability plan change million swiss franc record pharmaceutical division million swiss franc diagnostic division remain million swiss franc income allocate corporate mainly attributable previously divest business fund status balance sheet position mchf mchf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability overall funding status ifrs basis group define benefit plan decrease compare start year change came mainly increase define benefit obligation arise fall discount rate germany switzerland end use update mortality table increase define benefit obligation million swiss franc plan asset increase mainly increase market value investment fund status pension fund monitor local pension fund governance body closely review group level detail group pension postemployment benefit give note consolidated financial statement roche finance report roche group financial review roche share share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group consist roche healthcare company total shareholder return tsr define share price growth plus dividend measure swiss franc actual exchange rate constant exchange rate roche rank number yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group swiss franc term constant exchange rate healthcare sector outperform major segment general market despite continue pricing pressure government budget constraint part world roche share perform strongly year announcement marianne trial result late december affect closing value peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source datastream datum roche peer index rebase january peer index convert chf daily actual exchange rate currency fluctuation influence representation relative performance roche versus peer index roche finance report financial review roche group propose dividend board director propose increase dividend swiss franc share nonvoting equity security swiss franc approval annual general meeting consecutive increase dividend dividend proposal approve shareholder dividend payment total share nonvoting equity security billion swiss franc billion swiss franc result payout ratio base core net income base price yearend dividend yield roche share yield nonvoting equity security information roche security give page information share nonvoting equity security change chf chf chf eps basic eps diluted core ep basic core ep diluted equity attributable roche shareholder share dividend share detail refer note consolidated financial statement payout ratio calculate dividend share divide core earning share debt finance genentech transaction group issue bond note equivalent billion swiss franc debt raise early repay december billion dollardenominated note redeem follow exercise earlycall option december billion pound sterle billion dollar note repurchasedredeeme late year december group resolve exercise option early redemption billion dollar note march note repay march group finance intermune acquisition primarily raise net proceed billion dollar debt offering describe note consolidated financial statement remain financing achieve group fund issue commercial paper result low interest rate capital market group decide november restructure debt include early partial redemption billion dollardenominate note originally march july refinance issue billion dollardenominated note september november major debt restructuring result loss repurchase million swiss franc transaction describe note consolidated financial statement maturity schedule group bond note outstanding december show table include instrument issue prior genentech transaction roche finance report roche group financial review bond note nominal amount december contractual maturity dollar euro pound sterling swiss franc total total musd meur mgbp mchf musd mchf total total translate december exchange rate proceed bond note billion euro swap dollar financial statement bond note economic characteristic equivalent dollardenominate bond note proceed bond note million pound sterling swap dollar financial statement bond note economic characteristic equivalent dollardenominate bond note group plan meet debt obligation exist liquid fund cash generate business operation free cash flow billion swiss franc include cash generate operation payment interest tax dividend shortterm financing requirement group commercial paper programme issue billion dollar unsecured commercial paper note commit credit line billion euro available backstop line commercial paper note total billion dollar outstanding december december billion dollars longerterm financing group maintain strong longterm investmentgrade credit rating standard poor moodys facilitate efficient access international capital market credit rating roche group december shortterm longterm outlook moodys stable standard poor stable financial risk december group net debt position billion swiss franc billion swiss franc financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt redemption liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement cash marketable security mchf total mchf total cash cash equivalent money market instrument debt security equity security total cash marketable security roche finance report financial review roche group credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group billion swiss franc cash fix income marketable security remain strong invest aaaa range note previously group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position group trade receivables billion swiss franc begin increase financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country december trade receivable billion euro billion swiss franc public customer country decrease billion euro december mainly forfaite italy collection spain montoro plan group use different measure improve collection country include intense communication customer forfaite negotiation payment plan charge interest late payment legal action group apply new commercial policy select hospital greece portugal italy group trade receivable balance southern europe decrease liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year roche enjoy strong longterm investmentgrade credit rating standard poor moodys time roche rate high available shortterm rating agency event financing requirement rating strong credit roche permit efficient access international capital market include commercial paper market group commit credit line financial institution total billion swiss franc billion swiss franc serve stop line commercial paper programme december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price group var remain largely stable interest rate risk interest rate risk arise movement interest rate affect group financial result value group equity group use interest rate derivative manage interestraterelated exposure financial result information financial risk management financial risk var methodology include note consolidated financial statement international financial reporting standard roche group international financial reporting standard ifrs report consolidated result group implement minor amendment exist standard interpretation material impact group overall result financial position group currently assess potential impact new revise standard interpretation mandatory january group apply base analysis date group anticipate material impact group overall result financial position group assess new revise standard mandatory notably ifrs financial instrument ifrs revenue contract customer roche finance report roche group roche group consolidate financial statement roche group consolidate financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group consolidate financial statement roche group roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidate financial statement roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income remeasurement define benefit plan item reclassify income statement availableforsale investment cash flow hedge currency translation foreign operation item reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total roche finance report roche group consolidate financial statement roche group roche group consolidate balance sheet million chf december december december noncurrent asset property plant equipment goodwill intangible asset defer tax asset define benefit plan asset noncurrent asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer tax liability define benefit plan liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity roche finance report roche group roche group consolidate financial statement roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease net work capital payment define benefit plan utilisation provision disposal product operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination divestment subsidiary interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement equity contribution noncontrolle interest interest pay dividend pay equitysettle equity compensation plan net transaction equity financing cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december roche finance report roche group consolidate financial statement roche group roche group consolidate statement change equity millions chf non share retain fair value hedge translation control total capital earning reserve reserve reserve total interest equity year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest equity contribution noncontrolle interest december year end december january net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest equity contribution noncontrolle interest december roche finance report roche group note roche group consolidated financial statement note roche group consolidate financial statement general accounting principle basis preparation consolidate financial statement annual financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention item require account fair value approve issue board director january subject approval annual general meeting shareholder march financial statement annual financial statement roche holding ltd company register switzerland subsidiary group group significant accounting policy change accounting policy disclose note key accounting judgement estimate assumption preparation annual financial statement require management judgement estimate assumption affect report amount revenue expense asset liability contingent amount actual outcome differ management estimate estimate underlying assumption review ongoing basis base historical experience factor revision estimate recognise period estimate revise follow consider key accounting judgement estimate assumption believe appropriate base currently available information revenue nature group business sale transaction simple structure consist multiple component occur different time group party outlicense agreement involve upfront milestone payment occur year involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement circumstance level sale return revenue reliably measure case sale recognise right return expire generally prescription product patient order estimate management use publicly available information prescription information provide wholesaler intermediary december group million swiss franc provision accrual expect sale return chargeback rebate include medicaid similar rebate country estimate base analyse exist contractual legislatively mandate obligation historical trend group experience december group million swiss franc provision doubtful receivables note estimate base analyse age customer balance specific credit circumstance historical trend group experience take account current economic condition business combination group initially recognise fair value identifiable asset acquire liability assume non control interest consideration transfer business combination management judgement particularly involve recognition fair value measurement intellectual property inventory contingent liability contingent consideration make assessment management consider underlie economic substance item concern addition contractual term roche finance report note roche group consolidate financial statement roche group impairment december group million swiss franc property plant equipment note million swiss franc goodwill note million swiss franc intangible asset note goodwill intangible asset available use review annually impairment property plant equipment intangible asset use assess impairment trigger event provide evidence asset impair assess impairment exist estimate expect future cash flow actual outcome vary significantly estimate factor change discount rate plan use building machinery equipment closure facility presence competition technical obsolescence lower anticipate product sale lead short useful life impairment pension postemployment benefit group operate number define benefit plan fair value recognise plan asset liability base statistical actuarial calculation measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption december present value group define benefit obligation million swiss franc note actuarial assumption differ materially actual result change market economic condition long short life span participant change factor assess difference impact define benefit plan asset liability recognise balance sheet future period legal provision group provide anticipated legal settlement cost probable outflow resource reliably estimate december group million swiss franc legal provision status significant legal case disclose note estimate consider specific circumstance legal case relevant legal advice inherently judgemental highly complex nature legal case estimate change substantially time new fact emerge legal case progress reliable estimate provision record contingent liability disclose material environmental provision group provide anticipate environmental remediation cost probable outflow resource reasonably estimate december group million swiss franc environmental provision note environmental provision consist primarily cost fully clean refurbish contaminate site include landfill treat contain contamination certain site estimate inherently judgemental uncertainty relate detection previously unknown contamination method extent remediation percentage problematic material attributable group remediation site financial capability potentially responsible party estimate change substantially time new fact emerge environmental remediation progress contingent consideration provision group make provision estimate fair value contingent consideration arrangement arise business combination december group million swiss franc contingent consideration provision note total payment contingent consideration arrangement million swiss franc note estimate amount provide expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario discount net present value estimate change substantially time new fact emerge scenario develop income taxis december group current income tax net liability million swiss franc defer tax net asset million swiss franc note significant estimate require determine current defer tax asset liability estimate base interpretation exist tax law regulation factor impact current defer taxis include change tax law regulation rate change interpretation exist tax law regulation future level research development spending change pretax earning lease treatment leasing transaction mainly determine lease consider operating finance lease making assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment consolidation group periodically undertake transaction involve obtain control significant influence company transaction include equity acquisition asset purchase alliance agreement transaction structure entity case management make assessment group control significant influence company consolidated subsidiary account associate company make assessment management consider underlie economic substance transaction addition contractual term roche finance report roche group note roche group consolidate financial statement operating segment information group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party residual operating activity divest business certain global activity report corporate include corporate executive committee global group function communication human resource finance include treasury taxis pension fund management legal safety environmental service sub divisional information roche pharmaceutical chugai operate segment pharmaceutical division present divisional information million chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost segment information depreciation property plant equipment amortisation intangible asset impairment reversal property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense roche finance report note roche group consolidate financial statement roche group pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result operate profit elimination profit division operate profit capital expenditure business combination addition property plant equipment addition intangible asset total capital expenditure research development research development cost elimination cost division total segment information depreciation property plant equipment amortisation intangible asset impairment reversal property plant equipment impairment goodwill impairment intangible asset equity compensation plan expense net operating asset millions chf asset liability net asset pharmaceutical diagnostic corporate total operating nonoperating group net operating asset pharmaceutical subdivisional information million chf asset liability net asset roche pharmaceutical chugai elimination division pharmaceutical division roche finance report roche group note roche group consolidate financial statement information geographical area millions chf revenue external customer noncurrent asset royaltie property plant goodwill sale operate income equipment intangible asset switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total supplementary unaudited information sale therapeutic area pharmaceutical division business area diagnostic division give financial review sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenue major customer total national wholesale distributor represent approximately quarter group revenue national wholesale distributor amerisourcebergen corp billion swiss franc billion swiss francs mckesson corp billion swiss franc billion swiss franc cardinal health inc billion swiss franc billion swiss franc approximately revenue pharmaceutical operating segment residual diagnostic segment roche finance report note roche group consolidate financial statement roche group net financial expense financing cost millions chf interest expense amortisation debt discount net gain loss redemption repurchase bond note loss major debt restructure discount unwind net interest cost define benefit plan total financing cost financial income expense millions chf net gain loss sale equity security net gain loss equity security derivative dividend income writedown impairment equity security net income equity security interest income net gain loss sale debt security net interest income income debt security net foreign exchange gain loss net gain loss foreign currency derivative foreign exchange gain loss net financial income expense associate total financial income expense net financial expense million chf financing cost financial income expense net financial expense financial result treasury management financial result pension management associate net financial expense roche finance report roche group note roche group consolidate financial statement income taxis income tax expense millions chf current income taxis defer taxis total income tax expense group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate group average expect tax rate decrease main driver decrease low proportion group profit relatively high local tax rate average group rate low proportion profit drive goodwill impairment significant local tax rate change main operating area group compare group effective tax rate increase mainly goodwill impairment mention tax deductible utilisation previously unrecognise tax loss addition effective tax rate include retrospective reenactment research development tax credit mean result include year tax credit respect group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect nontaxable incomenondeductible expense equity compensation plan research development manufacturing tax credit state tax impact tax unremitted earning utilisation previously unrecognise tax loss difference group effective tax rate income tax benefit record respect equity compensation plan vary accord price underlie equity million swiss franc million swiss franc income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately million swiss franc million swiss franc record tax effect comprehensive income millions chf pretax aftertax pretax aftertax tax tax remeasurement define benefit plan availableforsale investment cash flow hedge currency translation foreign operation comprehensive income roche finance report note roche group consolidate financial statement roche group income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer taxis asset liability net defer tax asset liabilitie current income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay business combination charge credit income statement charge credit equity equity compensation plan transaction shareholder currency translation effect net current income tax asset liability december defer taxis movement recognise net asset liability millions chf property plant intangible define temporary equipment asset benefit plan difference total year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect december year end december january business combination charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect december defer tax net asset temporary difference mainly relate accrue liability provision unrealise profit inventory roche finance report roche group note roche group consolidated financial statement defer tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable tax applicable tax mchf rate mchf rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer tax liability establish withholding tax taxis payable remittance earning foreign subsidiary amount currently regard permanently reinveste total unremitted earning group regard permanently reinveste billion swiss franc december billion swiss franc business combination acquisition acquisition net asset acquire millions chf pharmaceutical diagnostic total intangible asset product intangible use product intangible available use technology intangible use defer tax asset inventory account receivable marketable security cash cash equivalent defer tax liability net asset liability net identifiable asset goodwill total consideration cash defer consideration contingent consideration settlement preexist relationship total consideration pharmaceutical seragon pharmaceuticals inc august group acquire control interest seragon pharmaceuticals inc seragon private company base san diego california acquisition group obtain right seragon entire portfolio selective estrogen receptor degrader serd potential treatment hormone receptorpositive cancer seragon lead product candidate arn nextgeneration serd currently phase clinical trial patient roche finance report note roche group consolidate financial statement roche group hormone receptorpositive breast cancer fail current hormonal agent seragon report pharmaceutical division total consideration million dollar million dollar pay cash million dollar defer cash consideration pay period date control end february million dollar arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero billion dollars santaris pharma september group acquire control interest santaris pharma santaris private company base near copenhagen denmark santaris pioneer proprietary locked nucleic acid lna platform contribute emerge era rnatargete therapeutic new class medicine potential address difficult treat disease range therapeutic area santaris report pharmaceutical division total consideration million dollar million dollar pay cash million dollar arise contingent consideration arrangement million dollar arise settlement preexist relationship contingent payment base achievement performancerelate milestone range undiscounted outcome zero million dollar intermune inc august group announce enter merger agreement intermune inc intermune fully acquire intermune price dollar share allcash transaction september group acquire control interest intermune publicly own company base brisbane california list nasdaq acquisition add new medicine idiopathic lung fibrosis esbriet group portfolio esbriet approve fda october idiopathic lung fibrosis progressive disease cause scar lung survival rate year diagnosis esbriet potential considerable difference treatment patient debilitate disease intermune report pharmaceutical division total consideration billion dollar pay cash september group issue billion dollar aggregate principal senior note finance transaction note dutalys gmbh december group acquire control interest dutaly gmbh dutalys private company base vienna austria dutalys specialise discovery development fully human bispecific antibodie base proprietary dutamab technology bispecific antibodie develop platform design provide novel bestinclass molecule therapeutic area dutalys report pharmaceutical division total consideration million dollar million dollar pay cash million dollar arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero million dollar identifiable asset acquire liability assume set table amount seragon santaris intermune dutalys provisional base preliminary information valuation asset liability subject adjustment pharmaceutical acquisition net asset acquire millions chf seragon santaris intermune dutalys total intangible asset product intangible use product intangible available use technology intangible use defer tax asset inventory account receivable marketable security cash cash equivalent defer tax liability net asset liability net identifiable asset goodwill total consideration cash defer consideration contingent consideration settlement preexist relationship total consideration roche finance report roche group note roche group consolidate financial statement fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate seragon santaris intermune valuation perform independent valuer intangible asset allocation dutalys base historical experience similar acquisition valuation complete independent valuer half fair value intermune inventory determine base estimate selling price ordinary course business estimate cost completion sale reasonable profit margin base effort complete sell inventory intermune account receivable comprise gross contractual amount million swiss franc expect collectable date acquisition goodwill represent control premium acquire work force synergy expect integrate acquire company group exist business intermune control premium represent premium pay trade market price obtain control business goodwill expect deductible income tax purpose directly attributable transaction cost million swiss franc report pharmaceutical operating segment general administration expense mainly relate intermune acquisition month december intermune contribute revenue million swiss franc net loss million swiss franc result report pharmaceutical division group acquisition occur january management estimate intermune contribute revenue million swiss franc net loss million swiss franc information provide illustrative purpose necessarily indicative result combine group occur intermune actually acquire beginning year indicative future result combine group impact seragon santaris dutalys acquisition result material diagnostic genia technologies inc june group acquire control interest genia technologies inc genia private company base california genia develop singlemolecule semiconductorbase dna sequence platform nanopore technology genia report diagnostic operating segment sequence business total consideration million dollar million dollar pay cash million dollar arise contingent consideration arrangement contingent payment base achievement performancerelate milestone arise june range undiscounte outcome zero million dollars iquum inc june group acquire control interest iquum inc iquum private company base massachusetts iquum develop laboratoryinatube liat system enable healthcare worker perform rapid molecular diagnostic testing pointofcare set close patient minimal training iquum report diagnostic operating segment molecular diagnostic business total consideration million dollar million dollar pay cash million dollar arise contingent consideration arrangement contingent payment base achievement performancerelate milestone arise half range undiscounted outcome zero million dollar addition group acquire control interest relate intellectual property hold company cash consideration million dollars bina technologies inc december group acquire control interest bina technologies inc bina private company base redwood city california bina provide big datum platform centralise management processing generation sequence datum bina proprietary onmarket genomic management solution binagm empower basic translational academic researcher perform fast scalable analysis maximise value genomic datum acquisition bina accelerate product development global commercialisation binagms enterprise software system support multiple sequence technology develop solution roche sequence system bina report diagnostic operating segment sequence business total consideration million dollar million dollar pay cash million dollar defer cash consideration pay period date control end million dollar arise contingent consideration arrangement contingent payment base achievement performancerelate milestone range undiscounted outcome zero million dollar roche finance report note roche group consolidate financial statement roche group identifiable asset acquire liability assume set table amount bina provisional base preliminary information valuation asset liability subject adjustment diagnostic acquisition net asset acquire millions chf genia iquum bina total intangible asset product intangible use product intangible available use defer tax asset inventory cash cash equivalent defer tax liability net asset liability net identifiable asset goodwill total consideration cash defer consideration contingent consideration total consideration fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate genia iquum valuation perform independent valuer intangible asset allocation bina base historical experience similar acquisition valuation complete independent valuer half goodwill represent control premium acquire work force synergy expect integrate acquire company group exist business goodwill expect deductible income tax purpose directly attributable transaction cost million swiss franc report diagnostic operating segment general administration expense impact genia iquum bina acquisition result report diagnostic division group material future acquisition ariosa diagnostics inc december group announce agreement acquire control interest ariosa diagnostics inc ariosa private company base san jose california january transaction close ariosa molecular diagnostic testing service provider provide highly target accurate noninvasive prenatal testing nipt service clia laboratory cellfree dna cfdna technology ariosas proprietary harmony prenatal test blood test perform early week pregnancy evaluate fetal cfdna find maternal blood test design assess risk syndrome genetic abnormality specifically test assess risk trisomie indicative extra chromosome fetus lead severe genetic condition harmony prenatal test validate clia requirement robust clinical datum set support clinical study ariosa report diagnostic operating segment sequence business purchase consideration million dollar cash million dollar contingent consideration arrangement roche finance report roche group note roche group consolidate financial statement foundation medicine inc january group announce agreement enter broad strategic collaboration foundation medicine inc fmi acquire majority interest fmi fully diluted basis fmi publicly own company base cambridge massachusetts list nasdaq stock code fmi group tender approximately million fmi share dollar share aggregate tender value approximately million dollar invest million dollar acquire million newly issue fmi share dollar share closing transaction expect second quarter transaction advance fmis marketleading position molecular information genomic analysis provide group unique opportunity optimise identification development novel treatment option cancer patient partnership include broad collaboration potential million dollar funding group accelerate fmis new product development initiative optimise treatment oncology patient well design understand result clinical trial base molecular information commercial collaboration agreement aim expand global sale effort fmis current future product plan fmi report pharmaceutical division trophos january group announce agreement acquire control interest trophos privately own company base marseille france closing transaction expect quarter trophos proprietary screening platform generate olesoxime tro develop spinal muscular atrophy sma rare debilitate genetic neuromuscular disease commonly diagnose child result pivotal phase clinical trial olesoxime sma show beneficial effect maintenance neuromuscular function individual type nonambulatory type iii sma reduction medical complication associate disease trophos report pharmaceutical division purchase consideration million euro cash million euro contingent consideration arrangement acquisition constitution medical investors inc july group acquire control interest constitution medical investors inc cmi private company base massachusetts cmi developer highly innovative hematology testing system design provide fast accurate diagnosis bloodrelate disease helping improve patient care cmi report diagnostic operating segment professional diagnostic business area total consideration million dollar million dollar pay cash million dollar arise contingent consideration arrangement contingent payment base achievement performancerelate milestone arise end range undiscounted outcome zero million dollar identifiable asset acquire liability assume set table acquisition net asset acquire millions chf cmi intangible asset product intangible available use defer tax liability net asset liability net identifiable asset goodwill total consideration cash contingent consideration total consideration cash flow business combination acquisition net cash outflow millions chf pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration pay deferred consideration pay contingent consideration pay cash acquire company transaction cost total net cash outflow roche finance report note roche group consolidate financial statement roche group global restructuring plan group continue implementation major global restructuring plan initiate prior year notably programme address longterm profitability diabetes care business diagnostic division total cost million swiss franc higher mainly result include income million swiss franc reversal previously incur impairment charge bulk drug production unit vacaville site california global restructuring plan cost incur millions chf diagnostic site consolidation plan total year end december global restructuring cost employeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost year end december global restructuring cost employeerelate cost site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost split plan table reformatte prior period reflect relative development plan include diabete care autonomy speed restructuring plan include closure nutley site associate infrastructure environmental remediation cost include plan pharmaceutical division research development strategic realignment intermune integration specialty care field force europe diagnostic division september roche diabetes care announce autonomy speed initiative enable business focus diabetes care specific requirement speed process decisionmake drive efficiency total cost million swiss franc incur mainly employeerelate cost consultancy cost spend small plan division million swiss franc include cost relate project restructure apply science business roche finance report roche group note roche group consolidate financial statement site consolidation operational closure site nutley new jersey complete schedule end group currently process divest site work remediate nutley site continue significant additional restructuring expense incur site consolidation cost include relate closure toluca mexico pharmaceutical graz austria diagnostic site global restructuring plan total cost million swiss franc major item goodwill impairment million swiss franc relate marcadia acquisition follow exit cardiovascular metabolic disease significant cost include million swiss franc relate field force reduction europe pharmaceutical division specialty care unit intermune integration cost million swiss franc cost million swiss franc arise implementation global outsourcing clinical trial monitoring pharmaceutical division remain minor plan total million swiss franc pharmaceutical division announce investment increase global biologic medicine manufacturing network capacity bulk drug production unit vacaville site california discontinue fully write service result income million swiss franc reversal previously incur impairment charge note global restructuring plan summary cost incur millions chf employeerelate cost termination cost define benefit plan employeerelate cost total employeerelate cost site closure cost impairment reversal property plant equipment accelerate depreciation property plant equipment gain loss disposal property plant equipment site closure cost total site closure cost reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental cost total cost roche finance report note roche group consolidate financial statement roche group global restructuring plan classification cost millions chf depreciation depreciation amortisation amortisation impairment cost total impairment cost total cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic general administration pharmaceutical diagnostic corporate total total operating segment roche pharmaceutical chugai diagnostic corporate total roche finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value year end december january business combination addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value impairment reversal charge october pharmaceutical division announce detail investment increase global biologic medicine manufacturing network capacity meet rise demand license biologic expect pipeline growth investment spread site penzberg germany basel switzerland vacaville oceanside bulk drug production unit vacaville site california license discontinue fully write reassessment global manufacturing network requirement time bulk drug production unit vacaville site require capital investment operational expect occur group decision restart licensing effort prepare operational use discontinue bulk drug production unit vacaville site commercial manufacturing result impairment reversal property plant equipment million swiss franc impairment reversal million swiss franc represent net book value time original impairment asset bring use depreciation charge intervene period impairment occur roche finance report note roche group consolidate financial statement roche group classification impairment property plant equipment million chf cost sale marketing distribution research development general administration total impairment reversal charge reimbursement receive insurance company respect impairment property plant equipment borrowing cost capitalise property plant equipment lease arrangement group lessee finance lease december capitalise cost property plant equipment finance lease million swiss franc million swiss franc net book value asset million swiss franc million swiss franc carry value lease obligation million swiss franc million swiss franc report debt note finance lease future minimum lease payment noncancellable lease million chf future minimum lease present value minimum lease payment payment year year year total future finance charge total future minimum lease payment undiscounte operating lease group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense million swiss franc million swiss franc operating lease future minimum lease payment noncancellable lease million chf year year year total minimum payment roche finance report roche group note roche group consolidate financial statement leasing arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method finance lease future minimum lease receipt noncancellable lease millions chf present value minimum gross investment lease lease receipt year year year total unearned finance income unguaranteed residual value net investment lease accumulate allowance uncollectible minimum lease payment million swiss franc million swiss franc contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straightline basis december machinery equipment original cost million swiss franc million swiss franc net book value million swiss franc million swiss franc lease party contingent rent recognise income operating lease future minimum lease receipt noncancellable lease millions chf year year year total minimum receipt capital commitment group noncancellable capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc roche finance report note roche group consolidate financial statement roche group goodwill goodwill movement carry value asset millions chf january cost accumulate impairment net book value year end december january business combination impairment charge currency translation effect december cost accumulate impairment net book value allocate follow cashgenerating unit roche pharmaceutical chugai total pharmaceutical division diabetes care professional diagnostic molecular diagnostic tissue diagnostic sequence strategic goodwill hold divisional level allocate business area total diagnostic division impairment charge impairment charge total million swiss franc record related goodwill impairment charge million swiss franc record writeoff goodwill tissue diagnostic business area diagnostic division impairment base late business plan prepare second half factor lead impairment decrease forecast cash flow follow reassessment late stage future product development return predesign phase combine additional reduction immunohistochemistry testing reimbursement laboratory business plan projection period reduce year year increase pretax discount rate impairment testing compare addition impairment million swiss franc record product intangible tissue diagnostic business note goodwill impairment charge million swiss franc record pharmaceutical division writeoff goodwill marcadia acquisition memory acquisition arius pirame acquisition deem disposed roche finance report roche group note roche group consolidated financial statement impairment charge total million swiss franc record related goodwill impairment charge million swiss franc record tissue diagnostic business area diagnostic division impairment base late business plan prepare second half main factor leading impairment reduce revenue expectation follow recent change college american pathologist guideline use negative reagent control immunohistochemistry testing reduce volume change reduce reimbursement laboratory april group announce reorganisation apply science business area goodwill impairment charge million swiss franc incur writeoff goodwill life sciences acquisition innovatis acquisition apply science business area impairment testing pharmaceutical division division operate segment cashgenerate unit test goodwill chugai recoverable base fair value cost sell determined reference publicly quote share price chugai share roche pharmaceutical recoverable impairment testing base value use cash flow projection roche pharmaceutical impairment testing base recent business plan approve management business plan include management late estimate sale volume pricing production operating cost assume significant change organisation business plan project year valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model data capital market include government twentyyear bond weight average tax rate calculation correspond pretax discount rate diagnostic division division business area cashgenerate unit test goodwill goodwill arise corangeboehringer mannheim acquisition goodwill ventana acquisition record monitor divisional level relate strategic development division meaningfully allocate division business area cashgenerate unit goodwill entire division recoverable impairment testing base value use cash flow projection base recent business plan approve management business plan include management late estimate sale volume pricing production operating cost assume significant change organisation business plan project year valuation include terminal value year assume growth discount rate base aftertax rate derive capital asset pricing model data capital market include government twentyyear bond weight average tax rate calculation correspond pretax discount rate sensitivity analysis management perform sensitivity analyse roche pharmaceutical diagnostic division increase discount rate combine decrease forecast cash flow chugai decrease publicly quote share price result sensitivity analysis demonstrate change key assumption cause carry value goodwill exceed recoverable december roche finance report note roche group consolidate financial statement roche group intangible asset intangible asset movement carry value asset millions chf product product intangible marketing technology intangible available intangible intangible use use use use total january cost accumulate amortisation impairment net book value year end december january business combination addition transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group year end december january business combination addition transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocation operating segment roche pharmaceutical chugai diagnostic total group roche finance report roche group note roche group consolidate financial statement significant intangible asset december millions chf remain operating segment net book value amortisation period product intangible use intermune acquisition roche pharmaceutical year tanox acquisition roche pharmaceutical year corangeboehringer mannheim acquisition diagnostic year iquum acquisition diagnostic year product intangible available use seragon acquisition roche pharmaceutical dutalys acquisition roche pharmaceutical cmi acquisition diagnostic genia acquisition diagnostic technology intangible use santaris acquisition roche pharmaceutical year classification amortisation impairment expense millions chf amortisation impairment cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic total internally generate intangible asset group currently internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful live intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination separate purchase december approximately project pharmaceutical division know decision point month certain circumstance lead impairment inherent uncertainty research development process intangible asset available use particularly risk impairment project expect result commercialise product roche finance report note roche group consolidate financial statement roche group intangible asset impairment impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment impairment charge pharmaceutical division impairment charge total million swiss franc record relate clinical datum assessment development project million swiss franc asset concern amortise fully write decision stop development compound acquire previous business combination million swiss franc asset concern amortise fully write decision stop development compound alliance partner million swiss franc asset concern amortise fully write reassessment project hepatitis virus hcv franchise million swiss franc mainly negative outcome arbitration competitor asset concern amortise fully write decision stop development compound million swiss franc asset concern amortise fully write decision stop collaboration project alliance partner million swiss franc asset concern amortise fully write diagnostic division impairment charge total million swiss franc record relate tissue diagnostic product intangible available use million swiss franc factor lead impairment reassessment late stage future product development return predesign phase demonstrate feasibility quality improvement asset concern use fully write tissue diagnostic product intangible use million swiss franc factor leading impairment decrease forecast cash flow follow reduction immunohistochemistry testing reimbursement laboratory increase assetspecific pretax discount rate impairment testing compare asset concern amortise write estimate recoverable value million swiss franc diabetes care technology intangible use million swiss franc factor leading impairment decrease forecast cash flow follow change timeline future product development increase asset specific pre tax discount rate impairment testing compare asset concern amortise write estimate recoverable value million swiss franc impairment charge pharmaceutical division impairment charge total million swiss franc record related portfolio reassessment hepatitis virus hcv franchise million swiss franc asset concern amortise write recoverable value million swiss franc portfolio reassessment cardiovascular metabolic disease franchise million swiss franc asset concern amortise fully write decision stop collaboration project alliance partner million swiss franc asset concern amortise fully write decision stop development compound alliance partner million swiss franc asset concern amortise fully write diagnostic division impairment charge total million swiss franc record apply science business area reorganisation asset concern amortise fully write roche finance report roche group note roche group consolidate financial statement potential commitment alliance collaboration group party inlicense similar arrangement alliance partner arrangement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration agreement group current estimate future thirdparty commitment payment set table figure undiscounte riskadjuste meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business potential future thirdparty collaboration payment december millions chf pharmaceutical diagnostic group year year year total inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory inventory expense cost sale total billion swiss franc billion swiss franc inventory writedown year result expense million swiss franc million swiss franc account receivable account receivable millions chf trade receivables note receivable receivables allowance doubtful account chargeback allowance total account receivable roche finance report note roche group consolidate financial statement roche group allowance doubtful account movement recognise liability million chf january additional allowance create unused amount reverse utilise year currency translation effect december bad debt expense marketing distribution total million swiss franc credit million swiss franc marketable security marketable security millions chf availableforsale financial asset equity security debt security money market instrument time account month investment total marketable security marketable security hold fund management purpose primarily denominate swiss franc dollar euro money market instrument contract mature year december debt security contract maturity million chf year year year total debt security cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent roche finance report roche group note roche group consolidate financial statement noncurrent asset noncurrent asset million chf availableforsale investment hold fair value availableforsale investment hold cost loan receivable longterm trade receivable restrict cash receivables total financial noncurrent asset longterm employee benefit asset total nonfinancial noncurrent asset associate total noncurrent asset availableforsale investment mainly equity investment private biotechnology company keep group strategic alliance effort unquoted equity investment classify availableforsale measure cost fair value measure reliably current asset current asset millions chf accrue interest income derivative financial instrument restrict cash receivables total financial current asset prepay expense tax recoverable asset total nonfinancial current asset total current asset receivables mainly relate royalty licensing income receivables roche finance report note roche group consolidate financial statement roche group account payable account payable million chf trade payable taxis payable dividend payable payable total account payable noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability longterm liability mainly relate accrued employee benefit current liability current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue chargeback allowance accrue royalty commission accrue liability total current liability roche finance report roche group note roche group consolidate financial statement provision contingent liability provision movement recognise liability million chf legal environmental restructure employee provision provision provision provision provision total year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company contingent consideration currency translation effect december current noncurrent december year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company defer consideration contingent consideration currency translation effect december current noncurrent december expect outflow resource year year year year december legal provision legal provision consist number separate legal matter include claim arise trade group company nature amount timing outflow difficult predict legal expense total million swiss franc million swiss franc reflect recent development legal matter detail major legal case outstanding disclose roche finance report note roche group consolidate financial statement roche group environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict significant provision discount time value money material significant provision relate closure site nutley new jersey estimate remediation cost landfill site near grenzach germany manufacturing operation close year ago restructure provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain provision discount time value money material matter pharmaceutical division significant provision relate specialty care field force restructure europe closure site nutley new jersey global outsourcing clinical trial monitor intermune integration diagnostic division significant provision relate restructure diabete care apply science business employee provision relate certain employee benefit obligation sabbatical leave longservice benefit timing cash outflow reasonably estimate base past experience provision time cash outflow nature uncertain provision relate item show table provision million chf sale return contingent consideration item total provision contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note roche finance report roche group note roche group consolidate financial statement pharmaceutical legal case accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal action relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder january approximately case dismiss december hlr defend approximately action involve approximately plaintiff bring federal state court personal injury allegedly result use accutane action allege ibd result accutane use hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation district court middle district florida tampa division july district court grant summary judgment favour hlr federal ibd case proceed august ruling affirm court appeal eleventh circuit plaintiff appeal multiple recently file matter remain pende action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county december juries superior court rule favour plaintiff case assess compensatory damage total million dollar case rule favour plaintiff superior court hlr process appeal case million dollar case verdict reverse favour hlr million dollar additional trial schedule individual trial result depend variety factor include unique particular case trial result date predictive future trial result group continue defend vigorously remain personal injury case claim avastinlucentis investigation february italian antitrust authority agcm announce investigation determine roche genentech novartis enter agreement restrict competition italian market drug reference particular avastin market roche lucentis market novartis avastin lucentis different drug develop approve different therapeutic purpose contain different active pharmaceutical ingredient march agcm issue verdict allege roche novartis collude artificially differentiate avastin lucentis order foster sale lucentis italy agcm fine roche million euro novartis million euro roche appeal agcm verdict tribunale amministrativo regionale del lazio tar december tar uphold decision agcm roche strongly disagree verdict tar appeal italian ministry health notify roche spa intention seek damage relate matter july roche pay million euro fine protest avoid additional penalty fee record expense general administration fine relate interest reimburse roche win case outcome matter determine time tarceva subpoena november genentech receive subpoena department justice doj request document information relate promotion tarceva prescription product initially approve treatment locally advanced metastatic nonsmall cell lung cancer failure prior chemotherapy regiman later approve additional indication genentech cooperate associate investigation civil criminal nature government representative present time government civil liability theory specifically genentech allegedly participate offlabel promotion tarceva cause submission false claim reimbursement civil false claim act subsequently genentech expect continue meeting communication government representative discuss company government respective view legal factual issue discuss negotiate mutuallyagreeable settlement possible request government genentech presentation reason company believe government decline criminal claim company number current andor genentech employee receive subpoenas grand jury testimony begin january outcome matter determine time roche finance report note roche group consolidate financial statement roche group rituxan arbitration october genentech biogen idec inc file complaint california sanofiaventis deutschland gmbh sanofiaventis llc sanofiaventis inc sanofi seek declaratory judgment certain genentech product include rituxan infringe sanofis patent nos patent invalid sanofi allege rituxan genentech product infringe certain claim patent march district court rule matter law genentech biogen idec infringe assert patent claim sanofi appeal court noninfringement rule appellate court affirm district court judgment patent infringement addition october sanofi affiliate hoechst gmbh hoechst file icc international court arbitration paris request arbitration genentech relate terminate patentlicense agreement hoechst predecessor genentech pertain abovementione patent relate patent outside hoechst seek payment patent license royalty sale certain genentech product include rituxan damage breach contract relief arbitral award september february arbitrator find genentech liable hoechst patentlicense royalty rituxan award royalty interest hoechst seek february group record royalty expense million swiss franc net assume reimbursement portion group obligation copromotion partner hoechst initiate proceeding france germany seek enforce arbitral awards october genentech pay award royalty interest hoechst protest genentech seek annulment arbitral award proceeding initiate court appeal paris hearing proceeding june september paris court appeal stay annulment proceeding seek guidance court justice specific legal question raise genentech relate arbitral award noncompliance competition law november hoechst file notice appeal french supreme court seek review paris court appeal decision seek guidance court justice outcome matter determined time average wholesale price litigation hlr roche laboratories inc rli approximately brand generic pharmaceutical company name defendant legal action relate price pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresent report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend awp action file state new jersey hlr rli vigorously defend matter limited fact discovery remain outstanding briefing class certification postpone second half trial date set matter outcome matter determined time pdl litigation august pdl biopharma pdl file complaint nevada genentech seek judicial declaration concern genentech obligation pay royalty certain exus sale herceptin avastin xolair lucentis agreement party september pdl file amend complaint assert additional claim genentech include breach contract breach imply covenant good faith fair dealing pdl assert new claim roche novartis intentional interference contractual relation addition declaratory relief pdl seek monetary damage include compensatory liquidate damage november genentech roche file motion dismiss failure state claim roche file additional motion dismiss lack personal jurisdiction july court deny motion pdl settle claim novartis addition litigation pdl conduct royalty audit relate sale avastin herceptin lucentis xolair raptiva year final audit report indicate pdls interpretation certain contract term genentech owe pdl additional royalty audit period interpretation genentech owe additional royalty year subsequent audit period group dispute pdls interpretation relevant contract term june pdl file demand arbitration relate audit claim american arbitration association january party agree settlement resolve dispute settlement agreement pdl agree dismiss claim genentech roche return genentech agree pay pdl single fix royalty rate end matter conclude roche finance report roche group note roche group consolidate financial statement gsk litigation september glaxosmithkline llc gsk genentech file patent lawsuit delaware california respectively lawsuit concerned gsk patent nos gsk assert claim genentech allege infringement patent herceptin lucentis seek compensatory damage lawsuit genentech seek judicial declaration noninfringement invalidity patent june party agree dismiss california action prejudice consolidate case proceed delaware august delaware court issue claim construction order construe term patent july party sign settlement agreement resolve dispute matter conclude boniva litigation hlr genentech roche affiliate collectively roche name defendant numerous legal action canada relate postmenopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause osteonecrosis jaw atypical femoral fracture december roche defend approximately action involve approximately plaintiff bring federal state court action bring court queen bench province saskatchewan canada personal injury allegedly result use boniva case early discovery stage litigation individual trial result depend variety factor include unique particular case roche vigorously defend matter outcome matter determine time ema investigation october european medicines agency ema announce start infringement procedure investigate allegation allege breach medicine safety report obligation relation centrally authorise medicine november ema announce result pharmacovigilance risk assessment committee assessment roche medicine ema find impact benefitrisk balance roche medicine confirm benefitrisk profile base available safety information ema health authority confirm medicine remain authorised change treatment advice patient healthcare professional corrective preventative action result inspection implement reinspection authority november lead certain finding roche address april ema issue report european commission summarise emas findings relation investigation european commission decide matter pursue financial penalty impose decision european commission matter pende outcome matter determine time roche finance report note roche group consolidate financial statement roche group debt debt movement carry value recognise liability millions chf january proceeds issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt net gain loss redemption repurchase bond note loss major debt restructuring amortisation debt discount business combination net foreign currency transaction gain loss currency translation effect december bond note commercial paper amount bank financial institution finance lease obligation borrowing total debt longterm debt shortterm debt total debt pledge group asset connection debt roche finance report roche group note roche group consolidate financial statement bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollardenominated note fix rate note march principal billion dollar isin usual usaq note september principal billion dollars isin usbc note march principal billion dollar outstanding billion dollars isin usuam usas note september principal billion dollars isin usba note september principal billion dollar isin usbb note september principal billion dollar isin usbe note march principal billion dollar outstanding billion dollars isin usuan usau note november principal billion dollar isin usbh dollardenominated note float rate note september principal billion dollar isin usbd note september principal billion dollar isin usaz european medium term note programme fix rate note march principal billion euro isin note march principal billion pound sterle outstanding million pound sterling isin note march principal billion euro outstanding billion euro isin note june principal billion euro isin note march principal billion euro isin note august principal million pound sterle outstanding million pound sterling isin swiss franc bond float rate note september principal billion swiss franc isin swiss franc bond fix rate bond march principal billion swiss franc isin bond september principal billion swiss franc isin bond september principal billion swiss franc isin genentech senior note senior note july principal billion dollar isin usag senior note july principal million dollar outstanding million dollar isin usac total bond note roche finance report note roche group consolidate financial statement roche group bond note maturity millions chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond pound sterling note total unamortised discount issuance bond note intermune acquisition september group finance intermune acquisition note combination group fund debt security commercial paper group raise net proceed approximately billion swiss franc debt offering describe newly issue debt senior unsecured guarantee roche holding ltd september group complete offer dollardenominate note group receive approximately billion swiss franc aggregate net proceed issuance sale fix float note term proceed note follows issuance dollardenominated note principal net proceed usd million chf million float rate note float rate note fix rate note fix rate note fix rate note fix rate note total major debt restructuring november group major debt restructure relate debt incur connection genentech transaction note group raise net proceed approximately billion swiss franc debt offering describe newly issue debt senior unsecured guarantee roche holding ltd debt repurchase million dollar fix rate genentech senior note july million dollar fix rate note march major debt restructuring result loss repurchase million swiss franc roche finance report roche group note roche group consolidate financial statement november group complete offer dollardenominate note group receive approximately billion swiss franc aggregate net proceed issuance sale fix note term proceed note follows issuance dollardenominated note principal net proceed usd million chf millions fix rate note fix rate note total issuance bond note group issue bond note redemption repurchase bond note partial repurchase pound sterlingdenominate note february group complete tender offer repurchase million pound sterling fix rate note march cash outflow million swiss franc plus accrued interest loss repurchase million swiss franc effective interest rate note partial redemption dollardenominated note december group resolve exercise option early partial redemption dollardenominate fix rate note march march group redeem outstanding principal million dollar equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow million swiss franc plus accrue interest additional million swiss franc loss record redemption effective interest rate note june group resolve exercise option early partial redemption dollardenominate fix rate note march august group redeem outstanding principal million dollar equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow million swiss franc plus accrued interest loss redemption million swiss franc effective interest rate note november group complete tender offer repurchase million dollar fix rate note march cash outflow million swiss franc plus accrued interest loss repurchase million swiss franc effective interest rate note partial repurchase genentech senior note november group complete tender offer repurchase million dollar fix rate senior note july cash outflow million swiss franc plus accrued interest loss repurchase million swiss franc effective interest rate note early redemption dollardenominated note december group resolve exercise option early partial redemption dollardenominate fix rate note march group redeem outstanding principal million dollar march equal sum present value remain schedule payment note discount redemption date treasury rate plus accrue unpaid interest principal cash outflow approximately million dollar plus accrue interest expect redemption group revise carrying value note account change amount timing estimate cash flow revise carrying value note december million dollar million swiss franc increase carry value million dollar million swiss franc record financing cost note loss redemption effective interest rate note roche finance report note roche group consolidate financial statement roche group redemption repurchase bond note group redeem billion euro note billion swiss franc bond date complete early redemption billion dollar note cash flow issuance redemption repurchase bond note cash inflow issuance bond note millions chf dollardenominated bond total cash inflow issuance bond note cash outflow redemption repurchase bond note millions chf european medium term note programme eurodenominate note european medium term note programme pound sterlingdenominate note dollardenominate note swiss francdenominate bond total cash outflow redemption repurchase bond note commercial paper roche holdings inc commercial paper program roche holdings inc establish commercial paper program issue billion dollar unsecured commercial paper note guarantee roche holding ltd commit credit line billion euro available backstop line maturity note program exceed day date issuance december unsecured commercial paper note principal billion dollar average interest rate outstanding movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december amount bank financial institution amount denominate currency notably chinese renminbi argentine peso average interest rate amount outstanding million swiss franc december million swiss franc year roche finance report roche group note roche group consolidate financial statement equity attributable roche shareholder change equity attributable roche shareholder millions chf reserve retain share capital earning fair value hedge translation total year end december january net income recognise income statement availableforsale investment fair value gain loss take equity transfer income statement income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity december entire transfer income statement report financial income expense roche finance report note roche group consolidate financial statement roche group change equity attributable roche shareholder millions chf reserve retain share capital earning fair value hedge translation total year end december january net income recognise income statement availableforsale investment fair value gain loss take equity transfer income statement income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity change noncontrolle interest december entire transfer income statement report financial income expense genentech transaction group complete purchase noncontrolle interest genentech effective march base international accounting standard separate financial statement ias consistent international financial reporting standard consolidated financial statement ifrs adopt group transaction account equity transaction consequence carrying consolidate equity group time reduce billion swiss franc billion swiss franc allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policy roche finance report roche group note roche group consolidate financial statement share capital december authorise issue share capital roche holding ltd group parent company consist million share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share march shareholder group announce continue shareholder pooling agreement exist modify shareholder composition shareholder group pool voting right hold share correspond share issue figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool describe note base information supply group novartis ltd basel affiliates participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board director propose dividend business year swiss franc share nonvoting equity security approve result total distribution shareholder million swiss franc subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security million million share nonvoting equity security derivative instrument total equity instrument record equity original purchase cost december fair value share billion swiss franc nonvoting equity security billion swiss franc equity instrument hold group potential conversion obligation arise group equity compensation plan note roche finance report note roche group consolidate financial statement roche group reserve fair value reserve fair value reserve represent cumulative net change fair value availableforsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai consolidated subsidiary chugai fully consolidated subsidiary group base group interest chugai december roche relationship chugai found basic alliance licensing research collaboration agreement common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement accordance international financial reporting standard ifrs file quarterly basis tokyo stock exchange certain consolidation entry minor difference chugais standalone ifrs result result chugai consolidated roche group accordance ifrs financial information chugai summarise financial information millions chf income statement sale royalty operating income total revenue operate profit balance sheet noncurrent asset current asset noncurrent liabilitie current liability total net asset cash flow cash flow operating activity cash flow invest activity cash flow financing activity roche finance report roche group note roche group consolidate financial statement dividend dividend distribute party hold chugai share total million swiss franc million swiss franc record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany item roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai licensing agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche rest world umbrella right agreement exclude japan south korea sign revise amend restate rest world umbrella right agreement exclude japan south korea taiwan sign august agreement roche right refusal development marketing chugais development compound market outside japan exclude south korea taiwan agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment arm length basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis research collaboration agreement roche chugai enter research collaboration agreement area small molecule synthetic drug research biotechnologybase drug discovery roche finance report note roche group consolidate financial statement roche group noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement chugai noncontrolle interest total net income recognise income statement availableforsale investment cash flow hedge currency translation foreign operation remeasurement define benefit plan comprehensive income net tax total comprehensive income dividend noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity change noncontrolle interest equity contribution noncontrolle interest december chugai noncontrolle interest total noncontrolle interest employee benefit employee remuneration million chf wage salary social security cost define contribution plan operating expense define benefit plan equity compensation plan termination cost employee benefit employee remuneration include operating result net interest cost define benefit plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit roche finance report roche group note roche group consolidate financial statement pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan define contribution plan define contribution plan fund payment employee group fund administer party group expense plan million swiss franc million swiss franc asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution group major define contribution plan notably roche saving plan define benefit plan plan usually establish trust independent group fund payment group company employee case notably major define benefit plan germany plans unfunded group pay pension retire employee directly financial resource plan usually govern senior governing body board trustee typically compose employee employer representative funding plan determine local regulation independent actuarial valuation separate independent actuarial valuation semiannual update prepare accordance requirement ias use group financial statement group major pension plan locate switzerland germany total account group define benefit obligation pension plan switzerland current pension arrangement employee switzerland plan govern swiss federal occupational old age survivor disability pension act bvg group pension plan administer separate legal foundation fund regular employee company contribution final benefit contributionbase certain minimum guarantee minimum guarantee swiss plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan underfunding remedie measure increase employee company contribution lower interest rate retirement account balance reduce prospective benefit suspension early withdrawal facility past service cost include million swiss franc income record respect change group pension plan switzerland change represent adoption low conversion rate determine annuity normal retirement age pension plan group major define benefit plan close new member new employee join define contribution plan large remain define benefit plan fund pension plan include separate plan originate nutley palo alto indianapoli site small unfunded supplementary retirement plan benefit base high average annual rate earning specify period length employment plan noncontributory employee group make periodic payment plan payment group million dollar million dollar underfunding normally remedie additional company contribution pension plan offer defer vested member settle define benefit obligation lump sum payment total lump sum payment define benefit asset million dollar million swiss franc settle obligation million dollar million swiss franc lead gain million dollar million swiss franc include settlement gain roche finance report note roche group consolidate financial statement roche group pension plan germany group major pension arrangement germany govern occupational pension act betravg plan unfunded group pay pension retire employee directly financial resource plan noncontributory employee benefit base final salary length employment plan close new member replace new plan fund regular employee company contribution administer contractual trust agreement final benefit contributionbase minimum guarantee minimum guarantee plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan past service cost include million swiss franc income record respect change group german pension plan change represent adoption increase normal retirement age pension plan rest world represent approximately group define benefit obligation consist number small plan country large pension plan chugai independently manage chugai main pension plan united kingdom chugai plan fully describe chugais ifrs financial statement pension plan fund regular employee company contribution benefit base final salary length employment plan close new member replace define contribution plan past service cost include million swiss franc income record respect change group pension plan reflect change indexation pension increase consumer price index instead previously retail price index postemployment benefit opeb plan represent approximately group define benefit obligation consist postretirement healthcare life insurance scheme mainly plan mainly unfunde contributory employee group reimburse retire employee directly financial resource group major define benefit opeb plan close new member cost plan reimbursable medicare prescription drug improvement modernization act statutory funding requirement plan group funding plan extent tax efficient payment group plan december ifrs funding status include reimbursement right fund opeb plan define benefit plan income statement millions chf post post pension employment total pension employment total plan benefit plan expense plan benefit plan expense current service cost past service income cost settlement gain loss total operating expense net interest cost define benefit plan total expense recognise income statement funding status fund group define benefit plan responsibility senior governing body board trustee sponsor employer manage base local statutory valuation follow legislation requirement respective jurisdiction plan establish qualified independent actuary carry statutory actuarial valuation regular basis actuarial assumption determine funding status statutory basis regularly assess local senior governing body funding status closely monitor corporate level fair value plan asset increase favourable market condition low discount rate compare result increase overall define benefit obligation result ifrs fund status fund define benefit plan decrease reimbursement right link postemployment medical plan represent expect reimbursement medical expenditure provide medicare prescription drug improvement modernization act roche finance report roche group note roche group consolidate financial statement define benefit plan fund status millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability report balance sheet define benefit plan asset define benefit plan liability plan asset responsibility investment strategy fund plan senior governance body board trustee asset liability study perform regularly major pension plan study examine obligation postretirement benefit plan evaluate investment strategy respect key financial measure expect return expect risk expect contribution expect funded status plan interdependent way goal assetliability study select appropriate asset allocation fund hold plan investment strategy develop optimise expect return manage risk contain fluctuation statutory fund status assetliability study include strategy match cash flow asset plan obligation group currently use annuity longevity swap manage longevity risk plan asset manage internal external asset manager actual performance continually monitor pension fund governance body closely monitor corporate level financial statement difference interest income actual return plan asset remeasurement record directly comprehensive income actual return plan asset gain million swiss franc gain million swiss franc recognition pension asset limit present value economic benefit available refund plan reduction future contribution plan define benefit plan fair value plan asset reimbursement right millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january interest income plan asset remeasurement plan asset currency translation effect employer contribution employee contribution benefit pay fund plan benefit pay settlement administration cost december roche finance report note roche group consolidate financial statement roche group define benefit plan composition plan asset millions chf equity security debt security property cash money market instrument investment december asset invest variety different class order maintain balance risk return follow equity debt security mainly quote market price level fair value hierarchy property mainly private commercial property fund mainly observable input level fair value hierarchy cash money market instrument mainly invest financial institution credit rating low investment mainly consist alternative mortgage commodity insurance contract risk management purpose mainly observable input level fair value hierarchy unobservable input level fair value hierarchy include fair value plan asset group share nonvoting security fair value million swiss franc million swiss franc debt instrument issue group fair value million swiss franc million swiss franc define benefit obligation define benefit obligation calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth mortality rate present value define benefit obligation determine discount estimate future cash outflow interest rate highquality corporate bond government bond countrie deep market corporate bond corporate government bond denominate currency benefit pay maturity term approximate term relate pension obligation group final salarybase define benefit pension plan germany united kingdom close new participant active employee member pension plan time close new participant continue accrue benefit final salarybase define benefit pension plan new employee join group define contribution plan new employee germany join contributionbase plan minimum guarantee define benefit pension plan switzerland final benefit contributionbase minimum guarantee remain open new employee result proportion define benefit obligation relate closed plan expect decrease future roche finance report roche group note roche group consolidate financial statement define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost remeasurement demographic assumption financial assumption experience adjustment currency translation effect employee contribution benefit pay fund plan benefit pay unfunded plan benefit pay settlement past service income cost settlement gain loss december composition plan active member defer vested member retire member december plan geography switzerland united states germany rest world december duration year actuarial assumption actuarial assumption financial statement base requirement set ias employee benefit unbiased mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management base advice actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate salary benefit level inflation rate cost medical benefit actuarial assumption vary base local economic social condition actuarial assumption statutory valuation differ base local legal regulatory requirement roche finance report note roche group consolidate financial statement roche group demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity rate employee turnover disability early retirement base historical behaviour group company average life expectancy assume individual age follow define benefit plan average life expectancy major scheme year male female country mortality table switzerland bvg generational table united states project germany heubeck table mortality table update increase overall define benefit obligation million swiss franc financial assumption base market expectation period obligation settle assumption actuarial valuation show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate salary increase expect rate pension increase expect inflation rate immediate medical cost trend rate ultimate medical cost trend rate discount rate determine reference interest rate highquality corporate bond government bond countrie deep market corporate bond expect rate salary increase base expected inflation rate adjustment reflect group late expectation longterm real salary increase expect rate pension increase generally link expected inflation rate expect inflation rate derive look level inflation imply financial market conjunction economist price inflation forecast historic price inflation economic variable circumstance medical cost trend rate account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development sensitivity analysis measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption follow table summarise impact change assumption present value define benefit obligation define benefit plan sensitivity define benefit obligation actuarial assumption millions chf year increase life expectancy discount rate increase decrease expect inflation rate increase decrease immediate medical cost trend rate increase decrease sensitivity analysis consider change assumption time leave assumption unchanged approach show isolated effect change individual assumption account assumption relate method carry sensitivity analysis prior year roche finance report roche group note roche group consolidate financial statement cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately million swiss franc include estimate million swiss franc additional contribution relate define benefit plan benefit pay unfunded plan estimate approximately million swiss franc relate german define benefit plan equity compensation plan group operate equity compensation plan include separate plan chugai ifrs sharebase payment require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense equity compensation plan roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan roche connect roche option plan bonus stock award chugai stock acquisition right total operating expense equitysettle cashsettle roche finance report note roche group consolidate financial statement roche group cash inflow outflow equity compensation plan millions chf roche option plan exercise chugai stock acquisition right exercise roche connect cost transaction equity total cash inflow outflow equitysettle equity compensation plan net transaction equity net cash outflow transaction equity mainly arise sale purchase equity instrument hold group potential conversion obligation arise group equity compensation plan note equity compensation plan roche stocksettle stock appreciation right group issue stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity security grant date exercise date roche ssar plan million ssar available issuance tenyear period right nontradable equitysettle award sevenyear duration vest phase basis year roche ssar movement number right outstanding weighted average weight average number right exercise price number right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable number weight average weight average number weight average outstanding year remain exercise price exercisable exercise price year grant thousands contractual life chf thousand chf total roche restrict stock unit plan group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance condition currently performance condition outstanding rsus december roche rsu plan million nonvoting equity security available issuance tenyear period roche rsu plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant roche finance report roche group note roche group consolidate financial statement roche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december vest transferable roche performance share plan group offer future nonvoting equity security awards discretion board director cash equivalent certain director key senior manager nontradable equitysettle award programme currently operate annual threeyear cycle roche psp plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director award result zero nonvoting equity security value adjustment depend achievement performance target roche performance share plan term outstanding award december number award outstanding thousand vest period year year year allocate recipients feb feb feb fair value unit grant chf total fair value grant chf million roche connect programme enables employee worldwide certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allows employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million cost plan million swiss franc million swiss franc roche option plan programme country ssar award plan employee right purchase nonvoting equity security exercise price specify grant date option nontradable equity settle award sevenyear duration vest phase basis year subject continued employment roche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche finance report note roche group consolidate financial statement roche group roche option plan term option outstanding december option outstanding option exercisable weighted average weighted average weight average number outstanding year remain exercise price number exercisable exercise price year grant thousands contractual life chf thousand chf total weighted average share price roche nonvoting equity security year swiss franc swiss franc bonus stock awards chairman board director humer chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number award fair value award calculate grant date chugai stock acquisition right chugai stock acquisition right programme total fair value right issue equivalent million swiss franc million swiss franc right issue employee director chugai right nontradable equitysettle award tenyear duration vest year right entitle holder purchase chugai share specify exercise price addition right issue director chugai thirtyyear duration vest holder retirement director chugai right entitle holder purchase chugai share exercise price japanese yen fair value measurement input measurement fair value grant date equity compensation plan follow fair value measurement roche stocksettle roche stock appreciation roche restrict performance share roche option right stock unit plan plan plan progressively cliff vest cliff vest progressively vest period year year year year contractual life year year number grant year thousand weight average fair value chf model binomial market price monte carlo binomial input option pricing model share price grant date chf exercise price chf expect volatility expect dividend yield early exercise factor expect exit rate fair value roche rsus equivalent share price date grant input parameter covariance matrix roche individual company peer group base threeyear history riskfree rate minus valuation take account define rank performance structure determine payout plan volatility determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour roche finance report roche group note roche group consolidate financial statement earning share nonvoting equity security basic earning share nonvoting equity security net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number share nonvoting equity security hold million weight average number share nonvoting equity security issue million basic earning share nonvoting equity security chf dilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf roche finance report note roche group consolidate financial statement roche group statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense financing cost financial income expense income taxis operate profit depreciation property plant equipment amortisation intangible asset impairment goodwill impairment intangible asset impairment reversal property plant equipment operating income expense define benefit plan operate expense equitysettle equity compensation plan net income expense provision bad debt reversal expense inventory writedown net gain loss disposal product adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity roche finance report roche group note roche group consolidate financial statement dividend pay millions chf dividend roche group shareholder dividend noncontrolle shareholder chugai dividend noncontrolle shareholder increase decrease dividend payable dividend withholding tax total significant noncash transaction significant noncash transaction contingent consideration arrangement arise business combination note risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral business planning controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director roche chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset account receivable december group trade receivables billion swiss franc billion swiss franc subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective trade receivables management maximise collection unpaid amount roche finance report note roche group consolidate financial statement roche group december group combine trade receivable balance national wholesale distributor amerisourcebergen corp mckesson corp cardinal health inc equivalent billion swiss franc represent group consolidate trade receivable billion swiss franc represent significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral hold trade receivables financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country trade receivable billion swiss franc billion swiss franc public customer country december trade receivables italy spain greece portugal decrease improved collection compare group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action nature geographic location counterpartie account receivable overdue impair show table include balance national wholesalers southern europe public customer describe account receivable overdue nature geographical location counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland europe north america latin america japan asia australia oceania rest world total age account receivable impair show table age account receivable impair millions chf overdue impair overdue month overdue month overdue month overdue month overdue year total account receivable cash marketable security december group cash marketable security billion swiss franc billion swiss franc subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly investment marketable security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity cash shortterm time deposit subject rule limit group exposure individual financial institution roche finance report roche group note roche group consolidate financial statement rate analysis cash fix income marketable security market value mchf total mchf total aaarange aarange arange bbbrange bbbrange unrated total master netting agreement group enter derivative transaction collateral agreement international swap derivative association isda master netting agreement respective counterpartie order mitigate counterparty risk agreement amount owe counterparty single day respect transaction outstanding currency aggregate single net payable party isda agreement meet criterion offset balance sheet group currently enforceable right offset recognise amount right offset enforceable occurrence future event default credit event contract term december significant financial asset term renegotiate impairment loss total impairment loss availableforsale financial asset amount million swiss franc million swiss franc liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement december group unused committed credit line financial institution total billion swiss franc billion swiss franc billion swiss franc serve backstop line commercial paper programme remain undiscounted cash flow contractual maturity financial liability include estimate interest payment show table contractual maturity financial liability millions chf carry value total year year year year year end december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability year end december debt bond note debt contingent consideration account payable derivative financial instrument total financial liability roche finance report note roche group consolidate financial statement roche group market risk market risk arise change market price mainly foreign exchange rate interest rate group financial asset financial liability affect group financial result equity valueatrisk group use valueatrisk var measure impact market risk financial instrument var indicate value range give financial instrument fluctuate preset probability result movement market price var calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate actual future gain loss associate treasury activity differ materially var analysis inherent limitation associate predict timing change interest rate foreign exchange rate equity investment price particularly period high market volatility furthermore var include effect change credit spread market risk financial instrument millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component decrease mainly age restructure debt environment largely stable rate major economy foreign exchange component decrease favourable exposure mix price component arise mainly movement equity security price increase group hold equity security foreign exchange risk group use swiss franc report currency result expose movement foreign currency mainly dollar japanese yen euro objective group foreign exchange risk management activity preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group use forward contract foreign exchange option crosscurrency swap hedge transaction exposure application instrument intends continuously lock favourable development foreign exchange rate reduce exposure potential future movement rate interest rate risk group mainly raise debt fix rate basis bond note group expose movement interest rate mainly dollar swiss franc eurodenominate float rate financial instrument primary objective group interest rate management protect net interest result group use forward contract option swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure interest rate hedging group enter follow interest rate hedge contract interest rate swap contract combine notional principal million dollar swap fix interest rate effective float interest rate month usdlibor plus average spread maturity swap september interest rate swap contract combine notional principal billion swiss franc swap fix interest rate effective float interest rate month usdlibor plus average spread maturity swap september roche finance report roche group note roche group consolidate financial statement price risk price risk arise mainly movement price equity security group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment capital management group define capital manage group total capitalisation sum debt plus equity include non control interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event capitalisation report senior management group regular internal management reporting show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group net equity significantly impact genentech transaction note group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai note chugai public company objective policy process manage capital determine local management roche finance report note roche group consolidate financial statement roche group financial instrument accounting classification fair value fair value financial asset liability carry value show consolidated balance sheet follow carry value fair value financial instrument millions chf fair value total available hedge fair value loan financial carry forsale instrument designate receivables liability value fair value year end december noncurrent asset availableforsale investment financial noncurrent asset account receivable marketable security cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability year end december noncurrent asset availableforsale investment financial noncurrent asset account receivable marketable security cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable derivative financial instrument total financial liability fair value bond note level calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period roche finance report roche group note roche group consolidate financial statement fair value hierarchy table analyse financial instrument carry fair value valuation method different level define follow level quote price unadjuste active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial instrument millions chf level level level total year end december marketable security equity security debt security money market instrument time account month derivative financial instrument availableforsale investment hold fair value financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value year end december marketable security equity security debt security money market instrument time account month derivative financial instrument availableforsale investment hold fair value financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument group determine level fair value follow valuation technique marketable security derivative financial instrument base valuation model use observable market datum interest rate yield curve foreign exchange rate imply volatility similar instrument measurement date availableforsale investment valuation model derive recently publish observable financial price group recognise transfer level fair value hierarchy end report period transfer occur significant transfer level level vice versa year roche finance report note roche group consolidate financial statement roche group level fair value detail determination level fair value measurement transfer level fair value hierarchy set contingent consideration arrangement millions chf january arise business combination acquire business combination total unrealised gain loss include income statement unused amount reverse additional create discount unwind total gain loss include comprehensive income currency translation effect transfer level utilise december contingent consideration arrangement group party certain contingent consideration arrangement arise business combination fair value determine consider expect payment discount present value riskadjusted average discount rate expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario significant unobservable input forecast sale performance criterion riskadjuste discount rate estimate fair value increase forecast sale performance criterion rate high riskadjuste discount rate low december total payment contingent consideration arrangement million swiss franc million swiss franc significant contingent consideration arrangement relate seragon santaris dutalys iquum genia cmi acquisition derivative financial instrument group enter currency swap certain nonus dollar debt instrument cash collateral agreement enter counterpartie currency swap mitigate counterparty risk follow table set carry value derivative financial instrument amount subject master netting agreement derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative carry value derivative financial instrument derivative subject master netting agreement collateral arrangement net roche finance report roche group note roche group consolidate financial statement collateral arrangement fair value currency swap decrease mainly weak euro compare dollar result cash deliver group counterpartie movement cash collateral receivable accrue liability millions chf january net cash deliver group december hedge accounting december group follow cash flow hedge fair value hedge designate qualifying hedge relationship cash flow hedge group enter crosscurrency swap hedge foreign exchange interest rate risk bond note issue group denominate euros sterling december instrument record fair value asset million swiss franc liability million swiss franc asset million swiss franc ineffective portion chugai enter foreign exchange forward contract hedge foreign translation exposure swiss franc dollar december instrument record fair value asset million swiss franc asset million swiss franc ineffective portion expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table expect cash flow qualify cash flow hedge millions chf total year year total year year cash inflow cash outflow total cash inflow outflow undiscounte cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity expect cash flow qualify cash flow hedge impact profit loss million chf total year year total year year cash inflow cash outflow total cash inflow outflow change hedge reserve equity show note fair value hedge group enter interest rate swap hedge fixedterm debt instrument december instrument record fair value liabilitie million swiss franc million swiss franc fair value asset million swiss franc million swiss franc gain million swiss franc record interest rate swap loss million swiss franc fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument roche finance report note roche group consolidate financial statement roche group group equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure group enter forward contract designate qualify fair value hedge december instrument record fair value liabilitie million swiss franc liability million swiss franc loss million swiss franc record forward contract loss million swiss franc result forward contract offset change fair value hedge equity investment hold marketable security note net investment hedge group net investment hedge relate party control shareholder share capital roche holding ltd group parent company consist bearer share december base information supply group shareholder group pool voting right own share represent issue share group consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool andr hoffmann andreas oeri members board director roche holding ltd hoffmann receive remuneration total swiss franc swiss francs oeri receive remuneration total swiss franc swiss franc transaction group individual member shareholder group subsidiary associate list major group subsidiary associate include note transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associate key management personnel total remuneration key management personnel million swiss franc million swiss franc member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee franz humer member corporate executive committee roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member corporate executive committee member corporate executive committee participate certain equity compensation plan describe term vest condition fair value award disclose note new member corporate executive committee include table calendar year join cec similarly members corporate executive committee retire way year include calendar year leave cec roche finance report roche group note roche group consolidate financial statement remuneration member board director corporate executive committee millions chf salary include cashsettle bonus bonus stock award social security cost pension postemployment benefit equity compensation plans board fee employee benefit total purpose remuneration disclosure value equity compensation plan include bonus stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition detailed disclosure executive remuneration require swiss law include remuneration report include annual report page disclosure value equity compensation plan include bonus stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration member board director corporate executive committee ifrs basis table deduct bonus stock award ifrs basis equity compensation plan ifrs basis add bonus stock award swiss legal basis equity compensation plan swiss legal basis total remuneration member board director corporate executive committee swiss legal basis include social security cost board director annual report corporate executive committee annual report bonus stock awards chairman board director humer chief executive officer grant bonus stock award lieu cashsettle bonus financial year issue end april number award fair value award calculate grant date roche finance report note roche group consolidate financial statement roche group equity compensation plan member corporate executive committee receive equity compensation show follow table number right option award grant member corporate executive committee roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan contribution pay humer member corporate executive committee millions chf roche connect transaction member board director corporate executive committee pension total million swiss franc pay group corporate executive committee member million swiss franc subsequent retirement member board director humer receive million swiss franc advisory capacity chairman board define benefit plan transaction group define benefit plan employee group describe note subsidiary associate list company share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich valor share valor genussschein isin share isin genussschein market capitalisation chf japan chugai pharmaceutical ltd tokyo jpy stock exchange tokyo isin market capitalisation jpy nonliste company share capital equity interest country company city millions algeria roche algrie spa bab ezzouar dzd argentina productos roche qumica industrial buenos aire ars vanguardia productos farmacuticos vanprofarma buenos aire ars australia roche diabetes care australia pty limited bella vista aud roche diagnostics australia pty limited castle hill aud roche product pty limited dee aud austria dutalys gmbh vienna eur intermune austria gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostic gmbh vienna eur roche diagnostic graz gmbh graz eur visiomab gmbh vienna eur roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city millions azerbaijan roche azerbaijan llc baku azn bangladesh roche bangladesh limited dhaka bdt belarus fllc roche product limit minsk byr belgium roche brussels eur roche diagnostic belgium brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico farmacuticos paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada chempharm limited toronto cad hoffmannla roche limited toronto cad intermune canada inc burlington cad sapac corporation ltd john cad chile roche chile limitada santiago chile clp china roche china holding ltd shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche bogot cop costa rica roche servicios heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostic hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic producto roche dominicana santo domingo dop ecuador roche ecuador quito usd salvador productos roche salvador san salvador svc egypt rodiagnostic egypt trading sae giza egp roche egypt llc cairo egp estonia roche eesti tallinn eur finland roche diagnostic espoo eur roche espoo eur france institut roche recherche mdecine translationnelle sas boulognebillancourt eur intermune france sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostic france sas meylan eur roche sas boulognebillancourt eur ventana medical systems sas illkirch eur georgia roche georgia llc tbilisi gel germany intermune deutschland gmbh berlin eur galenus mannheim gmbh mannheim eur galenus mannheim pharma gmbh mannheim eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen eur roche diabetes care gmbh mannheim eur roche diabete care deutschland gmbh mannheim eur roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche mtm laboratories heidelberg eur roche pharma grenzachwyhlen eur roche pvt gmbh waiblingen dem swisslab gmbh berlin eur verum diagnostica gmbh munich eur ghana roche product ghana limit accra ghs greece roche hellas athens eur roche diagnostic hellas athens eur guatemala producto roche guatemala guatemala gtq honduras producto roche honduras tegucigalpa hnl roche finance report note roche group consolidate financial statement roche group share capital equity interest country company city millions hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche product india pvt ltd mumbai inr indonesia roche indonesia jakarta idr iran roche par ltd tehran irr ireland roche diabetes care limited irish branch dublin eur roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit il roche pharmaceutical israel ltd petach tikva il italy intermune srl milan eur roche diagnostic spa milan eur roche spa milan eur ivory coast roche cte divoire sarl abidjan xof jordan hoffmannla roche ltd jordan psc amman jod japan roche diagnostic tokyo jpy kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius ltl macedonia roche makedonija dooel skopje mkd malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd petale jaya myr syntex pharmaceutical sdn bhd kuala lumpur myr mauritius roche product mauritius limited quatre borne mur mexico producto roche mexico city mxn roche servicios mxico mexico city mxn moldova roche product limit srl chisinau mdl morocco roche casablanca mad myanmar roche myanmar company limited yangon usd netherland intermune benelux nieuwegein eur roche diabete care nederland almere eur roche diagnostic nederland almere eur roche finance europe woerden eur roche nederland woerden eur roche pharmholde woerden eur new zealand roche diagnostic limited auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua managua nio nigeria roche product limited lagos ngn norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd panama producto roche panam panama city pab producto roche interamericana panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd peru producto roche qumica farmacutica lima pen roche farma peru lima pen philippine roche philippines inc taguig city php poland roche diabetes care polska warsaw pln roche diagnostic polska warsaw pln roche polska warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostic rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druzba doo ljubljana eur south africa roche product proprietary limited illovo zar south korea roche diagnostics korea ltd seoul krw roche korea company ltd seoul krw roche finance report roche group note roche group consolidate financial statement share capital equity interest country company city millions spain andreu roche madrid eur intermune spain madrid eur roche diagnostic barcelona eur roche farma madrid eur syntex roche madrid eur sri lanka roche product colombo private limited colombo lkr sweden intermune nordics kista sek roche stockholm sek roche diagnostic scandinavia bromma sek switzerland hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf intermune international muttenz chf intermune schweiz gmbh muttenz chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabetes care ltd rotkreuz chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie tunis tnd turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah united arab emirate roche diagnostic middle east fzco dubai ae roche middle east fzco dubai ae united kingdom intermune bristol limited london gbp intermune holding limited london gbp intermune limited london gbp intermune limited london gbp pirame limited welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostics ltd burgess hill gbp roche hold limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation branford usd anadys pharmaceuticals inc south san francisco usd bina technologies inc redwood city usd bioveris corporation indianapoli usd genentech inc south san francisco usd genentech usa inc south san francisco usd genia technologies corp mountain view usd hlr consumer health inc nutley usd hoffmannla roche inc nutley usd igen international inc pleasanton usd intermune inc wilmington usd iquum inc marlborough usd marcadia biotech inc nutley usd roche carolina inc florence usd roche diabete care inc indianapoli usd roche diagnostic corporation indianapoli usd roche diagnostic hematology inc westborough usd roche diagnostic operation inc indianapoli usd roche health solution inc fisher usd roche holdings inc south san francisco usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche tcrc inc new york usd seragon pharmaceuticals inc wilmington usd spring bioscience corp pleasanton usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch hamilton uyu venezuela producto roche caracas vef vietnam roche vietnam ltd chi minh city usd share capital local currency unit roche finance report note roche group consolidate financial statement roche group significant accounting policy consolidation policy subsidiary company include structured entity group control group control entity group expose right variable return involvement entity ability affect return power entity company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control associate company group exercise power exercise significant influence control account equity method segment report purpose segment report group corporate executive committee cec consider group chief operating decision maker determination group operate segment base organisation unit information report cec regular basis information provide basis segment revenue profit disclosure report note geographic analysis base location customer select segment balance sheet information routinely provide cec transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation annual financial statement present swiss franc group company use local currency functional currency certain group company use currency dollar swiss franc euros functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer comprehensive income consolidation asset liability group company functional currency swiss franc translate swiss franc yearend rate exchange income statement statement cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly comprehensive income roche finance report roche group note roche group consolidate financial statement revenue sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude value add taxis taxis directly link sale revenue sale product recognise transfer customer significant risk reward trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid similar rebate country deduct sale record accrue liability provision deduction account receivable estimate base analyse exist contractual legislatively mandate obligation historical trend group experience circumstance level sale return revenue reliably measure sale recognise right return expire generally prescription product patient revenue record earn service perform single transaction split separately identifiable component reflect substance transaction necessary conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation achievement normal production capacity expense incur research development internal research development activity expense incur follow internal research cost incur purpose gain new scientific technical knowledge understand internal development cost incur application research finding knowledge plan develop new product commercial production development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation intangible asset meet prior obtain marketing approval regulatory authority major market postmarkete study regulatory approval phase cost pharmaceutical business generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure acquire inprocess research development resource obtain inlicense arrangement business combination separate asset purchase capitalise intangible asset acquire asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy subsequent internal research development cost incur post acquisition treat way internal research development cost research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition asset license milestone upfront receipt royalty income recognise accrual basis accordance substance respective licensing agreement collectability royalty reasonably assure royalty recognise revenue cash receive certain group company receive upfront milestone similar payment party relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement upfront payment licence fee subsequent deliverable initially report deferred income recognise income earn period development collaboration manufacturing obligation roche finance report note roche group consolidate financial statement roche group employee benefit shortterm employee benefit include wage salary social security contribution pay annual leave sick leave profit share bonus nonmonetary benefit current employee cost recognise operating result employee render associate service group recognise liability profit share bonus contractually oblige past practice create constructive obligation longterm employee benefit include longservice sabbatical leave longservice benefit longterm disability benefit expect cost benefit accrue period employment change carry value longterm employee benefit liability recognise operating result termination benefit payable employment terminate group normal retirement date employee accept voluntary redundancy exchange benefit termination cost recognise early group long withdraw offer benefit group recognise related restructuring cost pension postemployment benefit define contribution plan group contribution recognise operating result employee render associated service prepay contribution recognise asset extent cash refund reduction future payment available define benefit plan liability recognise balance sheet present value define benefit obligation fair value plan asset change net define benefit liability recognise occur follows recognise income statement current service cost charge appropriate income statement head operating result past service cost include curtailment gain loss recognise immediately general administration operating result settlement gain loss recognise general administration operating result net interest net define benefit liability recognise financing cost recognise comprehensive income actuarial gain loss arise experience adjustment difference previous assumption actually occur change actuarial assumption return plan asset exclude amount include net interest net define benefit liability change limit recognition plan asset exclude amount include net interest net define benefit liability net interest net define benefit liability comprise interest income plan asset interest cost define benefit obligation interest effect limit recognition pension asset net interest calculate discount rate calculate define benefit obligation apply net define liability start period take account change contribution benefit payment pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan equity compensation plan fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity roche finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee finance lease exist substantially risk reward ownership transfer group finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt finance lease asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method operating lease exist substantially risk reward ownership transfer group payment operating lease charge income straightline basis period lease group lessor certain asset mainly diagnostic instrument lease party finance operating lease arrangement finance lease asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method operating lease asset report property plant equipment lease income operating lease recognise lease term straightline basis business combination business combination account acquisition method accounting date acquisition group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest acquire business consideration transfer measure fair value date acquisition group acquire ownership acquire business noncontrolle interest record fair value proportion fair value acquire net asset attributable noncontrolle interest directly attributable acquisitionrelated cost expense incur general administration expense goodwill goodwill arise business combination excess consideration transfer acquire business underlie fair value net identify asset acquire goodwill amortise test impairment annually occurrence indication impairment roche finance report note roche group consolidate financial statement roche group intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination initially record fair value available use intangible asset amortise straight line basis useful life intangible asset review impairment reporting date estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate useful life major class amortisable intangible asset follow product intangible use year marketing intangible use year technology intangible use year impairment property plant equipment intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost sell value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally year period extrapolate projection subsequent year discount appropriate longterm interest rate impairment loss arise useful life asset review necessary future depreciationamortisation charge accelerate impairment loss subsequently decrease decrease relate objectively event occurring impairment recognise previously recognise impairment loss reverse income statement impairment reversal impairment goodwill goodwill assess impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit recoverable cashgenerate unit high fair value cost sell value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss acquire business include cashgenerating unit permanently cease operate treat disposal business separately identifiable goodwill generate initial acquisition business factor goodwill entirely unrelated continue operation cashgenerating unit goodwill deem dispose fully impair impairment testing methodology describe note inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance allowance doubtful account record objective evidence group able collect amount estimate base specific indicator age customer balance specific credit circumstance group historical experience take account economic condition expense doubtful trade receivables recognise marketing distribution expense trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience roche finance report roche group note roche group consolidate financial statement cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash equivalent readily convertible know amount cash subject insignificant risk change fair value maturity month date acquisition provision contingency provision recognise legal constructive obligation incur probably lead outflow resource reliably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise discount time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available financial instrument financial instrument classify follow category disclose note availableforsale nonderivative financial asset designate classified financial asset category availableforsale asset initially record subsequently carry fair value change fair value record comprehensive income impairment interest foreign exchange component investment derecognise cumulative gain loss equity reclassify financial income expense availableforsale asset mainly comprise marketable security fair value hedge instrument derivative financial instrument manage exposure foreign currency interest rate equity market credit risk derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense fair value designate nonderivative financial instrument designate fair value profit loss initial recognition designate fair value instrument initially record subsequently carry fair value change fair value record income statement designate fair value instrument mainly comprise contingent consideration liability change fair value record general administration operating result loan receivables nonderivative financial asset fix determinable payment quote active market loan receivables initially record fair value subsequently carry amortise cost effective interest rate method impairment loss loan receivables mainly comprise account receivable cash cash equivalent financial liability nonderivative financial liability financial liability initially record fair value subsequently carry amortise cost effective interest rate method financial liability mainly comprise debt trade payable financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer financial liability derecognise contractual obligation discharge cancel expire roche finance report note roche group consolidate financial statement roche group impairment financial asset financial asset individually assess possible impairment reporting date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty available forsale equity security market value original cost market value original cost sustain sixmonth period consider impaired financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry comprehensive income difference original cost fair value impairment loss reverse reversal relate objectively event occurring impairment loss recognise debt security measure amortise cost availableforsale reversal recognise income equity security hold availableforsale reversal recognise directly comprehensive income hedge accounting group use derivative manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forwards contract option group generally limit use hedge account certain significant transaction qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income expense cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge instrument record fair value effective portion hedge include comprehensive income ineffective portion report financial income expense hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial item cumulative change fair value hedge instrument record comprehensive income include initial carrying value nonfinancial item date recognition cash flow hedge cumulative change fair value hedge instrument record comprehensive income include financial income expense forecast transaction affect net income fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income expense debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future roche finance report roche group note roche group consolidated financial statement defer tax asset liability recognise temporary difference tax basis asset liability carry value defer tax asset recognise extent probable future taxable profit available unused tax loss utilise current defer tax asset liability offset income taxis levy taxation authority legally enforceable right offset defer taxis determine base currently enact tax rate applicable tax jurisdiction group operate equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument hold group potential conversion obligation arise group equity compensation plan change accounting policy group adopt follow new standard amendment standard include consequential amendment standard date initial application january investment entity amendment ifrs ifrs ia offset financial asset financial liability amendment ias recoverable disclosure nonfinancial asset amendment ias novation derivative continuation hedge accounting amendment ias ifric levy material impact group overall result financial position future new revise standard group currently assess potential impact new revise standard interpretation mandatory january group apply base analysis date group anticipate material impact group overall result financial position group assess new revise standard mandatory notably ifrs financial instrument ifrs revenue contract customer subsequent event january swiss national bank announce discontinue minimum exchange rate swiss franc euro amount report annual financial statement reflect change foreign exchange rate december group use swiss franc presentation currency consolidated financial statement weaken foreign currency swiss franc negative currency translation impact group consolidated result report swiss franc date approval annual financial statement change foreign exchange rate cause material foreign exchange transaction gain loss group result group foreign exchange risk management disclose note currency translation sensitivity group result movement foreign currency exchange rate include financial review page roche finance report report roche management internal control financial reporting roche group report roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework version issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa issue report effectiveness group system internal control financial reporting report set christoph franz alan hippe chairman board directors chief financial officer basel january roche finance report roche group report statutory auditor consolidated financial statement report statutory auditor consolidated financial statement report statutory auditor general meeting shareholder roche holding ltd basel statutory auditor audit accompany consolidated financial statement roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flow statement change equity note page year end december board director responsibility board director responsible preparation consolidate financial statement accordance international financial reporting standard ifrs requirement swiss law responsibility include design implement maintain internal control system relevant preparation consolidate financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion consolidated financial statement base audit conduct audit accordance swiss law swiss auditing standard international standard auditing standard require plan perform audit obtain reasonable assurance consolidated financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure consolidated financial statement procedure select depend auditor judgement include assessment risk material misstatement consolidated financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation consolidated financial statement order design audit procedure appropriate circumstance audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation consolidated financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion consolidate financial statement year end december true fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ian starkey franois rouiller license audit expert auditor charge license audit expert basel january roche finance report report independent auditor internal control financial reporting roche group report independent auditor internal control financial reporting report independent auditor internal control financial reporting board director roche holding ltd basel examine roche group system internal control financial reporting december base criterion establish internal control integrate framework version issue committee sponsor organization treadway commission coso board director management roche holding ltd responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany report roche management internal control financial reporting responsibility express opinion company internal control financial reporting base examination entity internal control financial reporting process effect entitys board director management personnel design provide reasonable assurance reliability financial statement prepare accordance international financial reporting standard ifrs include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset entity provide reasonable assurance transaction record necessary permit preparation financial statement accordance applicable financial reporting framework provide reasonable assurance prevention timely detection unauthorised acquisition use disposition entitys asset material effect entitys financial statement conduct examination accordance international standard assurance engagement isae standard require plan perform examination obtain reasonable assurance effective internal control financial reporting maintain material respect examination include obtain understand internal control financial reporting testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe examination provide reasonable basis opinion inherent limitation internal control financial reporting include possibility management override control misstatement error fraud occur detect projection evaluation internal control financial reporting future period subject risk internal control inadequate change condition degree compliance policy procedure deteriorate opinion roche group maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework version issue committee sponsor organization treadway commission coso audit accordance swiss auditing standard international standard audit consolidated financial statement roche holding ltd year end december report date january express unqualified opinion consolidated financial statement kpmg ian starkey franois rouiller license audit expert auditor charge license audit expert basel january roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply retrospectively dividend propose board director roche finance report multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply retrospectively dividend propose board director roche finance report roche group multiyear overview supplementary information sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report multiyear overview supplementary information roche group addition property plant equipment division millions chf pharmaceutical diagnostic corporate total addition property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche group multiyear overview supplementary information supplementary core result ep information group basic diluted earning share give note annual financial statement allow transparent assessment actual result underlie performance business income statement group operating result division show ifrs core basis core result concept internal management business base ifrs result follow adjustment global restructuring plan note exclude amortisation impairment intangible asset note impairment goodwill note exclude acquisition accounting onetime impact alliance arrangement business combination financial review exclude discontinued operation currently exclude legal environmental expense financial review exclude global issue outside healthcare sector group control currently exclude material onetime treasury item major debt restructuring note exclude pension plan settlement note exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm group ifrs result include divisional breakdown reconcile core result table calculation core eps give table additional commentary adjustment item give financial review roche finance report multiyear overview supplementary information roche group core result reconciliation million chf alliance normali global intangible business legal major debt pension sation restruc amorti intangible combi environ restruc plan ecp tax ifrs ture sation impairment nation mental ture settlement benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result reconciliation million chf alliance normali global intangible business legal pension sation restruc amorti intangible combi environ plan ecp tax ifrs ture sation impairment nation mental settlement benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest roche finance report roche group multiyear overview supplementary information divisional core result reconciliation million chf alliance global intangible business legal pension restruc amorti intangible combi environ plan ifrs ture sation impairment nation mental settlement core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation million chf alliance global intangible business legal pension restruc amorti intangible combi environ plan ifrs ture sation impairment nation mental settlement core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report multiyear overview supplementary information roche group core ep basic core net income attributable roche shareholder chf million weight average number share nonvoting equity security issue million core earning share basic chf core ep diluted core net income attributable roche shareholder chf million increase noncontrolle interest share core net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue calculate diluted earning share million core earning share dilute chf roche finance report roche group multiyear overview supplementary information supplementary operating free cash flow information divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible asset impairment reversal property plant equipment impairment goodwill impairment intangible asset total adjustment add expense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct utilisation provision proceed disposal total operating profit cash adjustment ebitda core operate profit depreciation impairment property plant equipment core basis ebitda margin sale roche finance report multiyear overview supplementary information roche group supplementary balance sheet information net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset net operating asset balance sheet reconciliation million chf taxation pharmaceutical diagnostic corporate treasury roche group property plant equipment goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset roche finance report roche group roche security roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july information table restate change ratio adr effective january change ratio adr effective january change ratio adr effective february roche finance report roche security roche group number share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total number share nonvoting equity security genussscheine hold total issue datum share nonvoting equity security chf earning basic earning dilute core earning basic core earning dilute equity attributable roche shareholder dividend stock price share open high low yearend stock price nonvoting equity security genussschein open high low yearend market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price dividend propose board director ticker symbol share nonvoting equity security american depositary receipt adr swiss exchange rog bloomberg rog rhhby reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statement note financial statement summary significant accounting policy ignificant shareholder quity isk management contingent liability board executive shareholding appropriation available earning report statutory auditor financial statement financial statement roche holding ltd basel financial statement income statement millions chf year end december income income participation interest income loan group company interest investment income guarantee fee income group company income total income expense financial expense administration expense expense total expense profit taxis tax net income roche finance report roche holding ltd basel financial statement balance sheet millions chf december december noncurrent asset participation longterm loan group company total noncurrent asset current asset account receivable group company shortterm loan group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine legal reserve general legal reserve reserve equity instruments free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company unrealise foreign currency gain liability total current liability total liability total equity liability pro memoria nonvoting equity security nominal value roche finance report note financial statement roche holding ltd basel note financial statement summary significant accounting policy basis preparation financial statement roche holding ltd basel prepare accordance provision swiss law participation major participation company list note roche group annual financial statement valuation method translation foreign currency marketable security equity instrument report low cost market value asset include participation report cost appropriate writedown asset liability denominate foreign currency translate swiss franc yearend rate exchange participation translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer taxis tax charge include corporate income capital taxis equity share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate equity instrument company purchase roche share million roche share purchase price swiss franc share sell roche share roche share average sale price swiss franc share swiss franc share net gain million swiss franc net gain million swiss franc dividend income amount million swiss franc nil december remain roche share roche share net book value million swiss franc million swiss franc include marketable security roche finance report roche holding ltd basel note financial statement movement recognise amount million chf share legal free special available total capital reserve reserve reserve earnings equity january net income dividend transfer free reserve december net income dividend reserve equity instrument december net income dividend reserve equity instrument december contingent liability guarantee company issue guarantee certain bond note commercial paper credit facility group company nominal outstanding december billion swiss franc billion swiss franc describe note roche group annual financial statement significant shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company control shareholder december base information supply group shareholder group pool voting right own share represent issue share group consist vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri catherine oeri jrg duschmal lukas duschmal charitable foundation wolf shareholder pooling agreement exist figure include share pooled voting right hold outside group individual member group maja oeri member pool hold share represent voting right independently pool december base information supply group share share own novartis ltd basel include affiliate thereof participation roche finance report note financial statement roche holding ltd basel risk management detailed disclosure risk management require swiss law include note roche group annual financial statement board executive shareholdings board director director andr hoffmann andreas oeri certain member founder family closely associate belong shareholder group pool voting right end group hold share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table arthur levinson resign september annual general meeting march franz humer william burns stand reelection bernard poussot professor richard lifton nominate election new member board director agm march shareholdings member board director nonvoting equity security share genussscheine franz humer hoffmann baschera bell bulcke burn julius levinson oeri schwan voser weder mauro total include share hold shareholder group pool voting right equity compensation award roche option plan ssar rsus roche performance share plan schwan appoint board director march shareholdings disclose table member corporate executive committee roche finance report roche holding ltd basel note financial statement corporate executive committee member corporate executive committee person closely associate hold share nonvoting equity security show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan ayyoubi diggelmann hippe keller oday total equity compensation award roche option plan ssar rsus roche performance share plan close relative keller hold roche share roche share december members corporate executive committee hold roche option plan award rop stocksettle stock appreciation right ssar show table term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page rop ssar award hold december year issue total schwan ayyoubi diggelmann hippe keller oday total cec strike price chf expiry date mar mar mar feb feb feb july december members corporate executive committee hold restrict stock unit rsus show table term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page rsu award allocate individually remuneration committee discretion vest recipient year result nonvoting equity security remain block year rsu award hold december year issue total schwan ayyoubi diggelmann hippe keller oday total cec roche finance report note financial statement roche holding ltd basel december members corporate executive committee show table hold psp award psp performance cycle term vest condition award disclose note roche group annual financial statement additional supplementary information remuneration report include annual report page award result zero nonvoting equity security value adjustment depend achievement performance target discretion board director end cycle performance target achieve accordingly participant receive originally target nonvoting equity security total target number award outstanding performance cycle december show table roche performance share plan award hold december psp psp schwan ayyoubi diggelmann hippe keller oday total cec allocation date feb feb december william burns members corporate executive committee time hold total stock settle stock appreciation right restrict stock unit outstanding total award grant roche performance share plan roche finance report roche holding ltd basel appropriation available earning appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account roche finance report report statutory auditor financial statement roche holding ltd basel report statutory auditor financial statement report statutory auditor general meeting shareholder roche holding ltd basel statutory auditor audit accompany financial statement roche holding ltd comprise income statement balance sheet note page year end december board director responsibility board director responsible preparation financial statement accordance requirement swiss law company article incorporation responsibility include design implement maintain internal control system relevant preparation financial statement free material misstatement fraud error board director responsible selecting apply appropriate accounting policy make accounting estimate reasonable circumstance auditor responsibility responsibility express opinion financial statement base audit conduct audit accordance swiss law swiss auditing standard standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit involve perform procedure obtain audit evidence amount disclosure financial statement procedure select depend auditor judgement include assessment risk material misstatement financial statement fraud error make risk assessment auditor consider internal control system relevant entitys preparation financial statement order design audit procedure appropriate circumstance purpose express opinion effectiveness entity internal control system audit include evaluate appropriateness accounting policy reasonableness accounting estimate evaluate overall presentation financial statement believe audit evidence obtain sufficient appropriate provide basis audit opinion opinion opinion financial statement year end december comply swiss law company article incorporation report legal requirement confirm meet legal requirement license accord auditor oversight act aoa independence article article aoa circumstance incompatible independence accordance article paragraph item swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg ian starkey franois rouiller license audit expert auditor charge license audit expert basel january roche finance report publish cautionary statement forwardlooke statement hoffmannla roche ltd annual report contain certain forwardlooking statement basel switzerland forwardlooke statement identi fie word believe tel expect anticipate project intend seek estimate fax future similar expression discussion thing strategy goal plan intention factor cause actual result differ materially future reflect forward media office look statement contain annual report group communication pricing product initiative competitor legislative basel switzerland regulatory development economic condition delay inability tel obtain regulatory approval bring product market fax fluctuation currency exchange rate general financial market condition uncertaintie discovery development marketing new product new use exist product include investor relation limitation negative result clinical trial research project basel switzerland unexpected effect pipeline market product increase tel government pricing pressure interruption production loss fax inability obtain adequate protection intellectual property right litigation loss key executive employee adverse publicity news coverage website wwwrochecom statement earning share growth profit forecast interpret mean roche earning earning share subsequent period necessarily order publication match exceed historical publish earning earning share tel roche fax email baselwebmasterrochecom trademark mention enjoy legal protection roche finance report publish german english case annual general meeting doubt difference interpretation english version shall prevail march german text print nonchlorine bleach fsccertified paper roche annual report issue hoffmannla roche ltd basel group communicationsfhoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom roche finance report finance report